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ABSTRACT 
 The gastrointestinal tract is home to trillions of bacteria that interact with each 
other and with the host’s mucosal immune system. Obligate and facultative anaerobes 
thrive in the small and large intestine. While many of these bacteria have beneficial 
relationships with their host, opportunistic pathogens can bloom in times of inflammation 
and prolong disease. Klebsiella pneumoniae is an opportunistic pathogen that is part of 
the gut microbiota in many healthy individuals. Here we explore the population dynamics 
of K. pneumoniae in the gastrointestinal tract in mouse models of health and disease. 
 To assess the role of intra-species genomic diversity in interactions with the host, 
a mouse K. pneumoniae isolate and three human clinical isolates from human stool, 
sputum, and urine were studied in the T-bet-/- Rag2-/- and dextran sodium sulfate models 
of ulcerative colitis and in a mouse model of systemic neonatal infection. Regardless of 
host origin, isolate site source, or genomic differences, all four K. pneumoniae isolates 
were able to stimulate colonic inflammation. However, only exposure to the murine K. 
pneumoniae isolate, and not human clinical isolates, led to neonatal death. In addition, 
this murine isolate correlated with differential shifts in levels of other Enterobacteriaceae 
species in the colon. Murine K. pneumoniae was found in higher amounts in host 
mesenteric lymph nodes compared to human isolates, suggesting subtle strain-based 
differences that affect response to K. pneumoniae in the gastrointestinal tract. 
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! A defining feature of K. pneumoniae is its mucoid capsular polysaccharide coat. 
To begin investigating a role for K. pneumoniae’s capsule in the gastrointestinal tract, K. 
pneumoniae biogeography was assessed in gnotobiotic mice. Encapsulated K. 
pneumoniae were outcompeted by naturally arising variants with reduced capsule 
throughout the gastrointestinal tract of gnotobiotic mice, except in the distal small 
intestine. This portion of the small intestine was also the region with the highest host 
Paneth cell antimicrobial peptide expression. Micro-injection of K. pneumoniae into 
small intestinal organoids revealed increased growth of encapsulated K. pneumoniae in 
the presence of α-defensins and decreased survival of K. pneumoniae with reduced 
capsule production. Capsule also conferred an advantage when K. pneumoniae was part 
of a diverse microbiota. Competition assays between K. pneumoniae and Escherichia coli 
showed enhanced survival of encapsulated K. pneumoniae compared to isolates with 
reduced capsule production. These data suggest that host AMPs, in combination with 
bacterial-bacterial interactions, shape population dynamics of K. pneumoniae and select 
for encapsulated K. pneumoniae throughout the gastrointestinal tract. Overall, these 
studies provide a foundation for understanding interactions between K. pneumoniae, the 
host, and other bacteria in the gastrointestinal tract. 
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I. COPYRIGHT DISCLOSURE 
Adapted in part from Wardwell L, Huttenhower C, Garrett W. Current concepts 
of the intestinal microbiota and the pathogenesis of infection. Current Infectious Disease 
Reports 13(1), 28-34 (2011). 
II. OVERVIEW 
 The intestinal microbiome is the collection of bacteria, viruses, archaea, fungi, 
and parasites that reside in the gastrointestinal tract. Microbiome composition plays an 
important role in gut immune homeostasis and disruption of the microbiome can lead to 
dysbiosis and disease. Depending on host genetics and environmental factors, individual 
bacteria can be both beneficial and antagonistic to their host. For example, Klebsiella 
pneumoniae is an opportunistic pathogen found in the microbiome of healthy humans that 
can also cause pneumonia, urinary tract infections, diabetic liver abscesses, and 
bacteremia in susceptible individuals. Adding to K. pneumoniae’s clinical burden is the 
global spread of highly antibiotic-resistant strains. While several metabolic genes are 
known to be necessary for K. pneumoniae colonization of the gastrointestinal tract, an 
awareness of colonization factors and behavior in the gut is incomplete. Since K. 
pneumoniae colonization of the gastrointestinal tract predisposes patients for K. 
pneumoniae infection, understanding this bacterium in its disease reservoir is of the 
utmost importance. 
III. GASTROINTESTINAL MICROBIOTA AND THE INTESTINAL EPITHELIUM 
Bacterial cells outnumber eukaryotic cells in the human body by greater than ten-
fold.  In the gastrointestinal tract alone, there are up to 1012 microbes per gram of stool, 
corresponding to up to 100 trillion bacteria in the human gut and representing several 
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hundred distinct bacterial species. These bacteria, known collectively as the intestinal 
microbiota, play an important role in a multitude of host functions including energy 
extractions from food, production of microbial metabolites, development of the host’s 
immune system, and protection from and response to systemic and gastrointestinal 
infectious diseases (1, 2). These communities are in turn shaped by host genetics, diet, 
and the environment and thus exhibit substantial inter-individual variation (3). Advances 
in sequencing technology and the computational methodology to interpret these data have 
resulted in an increased appreciation for the role of gut microbiomes in the pathogenesis 
of obesity (4), inflammatory bowel disease (5), type 1 diabetes (6), and metabolic 
syndrome (7). 
Intestinal epithelium 
The gastrointestinal tract is divided into the small intestine (duodenum, jejunum 
and ileum), and the large intestine (colon). The intestinal epithelium is a single layer of 
cells separated from the microbial-rich lumen by a layer of mucus. Stem cells residing in 
the crypts of Lieberkuhn give rise to a variety of intestinal epithelial cells that are 
renewed every 4-5 days (8). Intestinal epithelial cells include enterocytes, mucus 
producing Goblet cells, enteroendocrine cells, antimicrobial producing Paneth cells, and 
Tuft cells. Intestinal epithelial cells are connected by tight junctions and form a barrier 
between the mucosal immune system and microbes within the lumen (9). 
Paneth cells are specialized secretory epithelial cells. Primarily found within the 
small intestine, Paneth cell concentrations increase in a descending manner and reach 
their height in the distal ileum (10). Paneth cells produce and granocytose antimicrobial 
peptides (AMPs) into the lumen to aide in pathogen defense and in shaping composition 
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of the microbiome (11, 12). In humans these antimicrobial peptides include two small, 
cationic α-defensins (α-defensin 5 and α-defensin 6), lysozyme, phospholipase A2, and 
RegIII α (13). In addition to these AMPs, murine Paneth cells produce many a-defensins, 
termed cryptdins, and angiogenin, an antimicrobial Rnase. Paneth cells constitutively 
produce AMPs with the exception of RegIIIγ (the mouse isoform of RegIIIα) and 
angiogenin, which are induced in the presence of symbiotic bacteria (13). Defects in 
Paneth cell function are associated with ileal Crohn’s disease, highlighting the 
importance of this cell in gastrointestinal immune homeostasis (14).  
Biogeography of gastrointestinal bacteria 
 Many bacteria of the upper digestive tract are killed by the harsh acidic pH of the 
stomach (pH<4) (15). Consequently, the duodenum, or proximal small intestine, is the 
area of the small and large bowel with the lowest concentration of luminal and mucosal 
bacteria. In addition to reducing numbers, selective pressures encountered in the stomach 
also affect diversity of bacterial communities. Large decreases in both phylogenetic and 
Shannon alpha diversity have been seen in the stomach and lower gastrointestinal 
bacterial communities as compared to those of the mouth (16). As bacteria move along 
the small intestine, total numbers and Shannon alpha diversity recover and reach a 
maximum in the cecum and throughout the colon.  
 Early studies on the microbiome have revealed phylum level differences in 
community composition according to gastrointestinal biogeography. The mouth 
microbiome is marked by a high relative abundance of Fusobacteria; Proteobacteria 
predominate in the stomach and retain a high representation in the proximal small 
intestine for some individuals (16). In contrast, the colon microbiome is dominated by 
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Gram-negative Bacteroidetes and Gram-positive Firmicutes, followed by less abundant 
gram-negative Proteobacteria (17). Rounding out the highly represented phyla of the 
colon microbiome are the Actinobacteria and Deferribacteres. In healthy individuals, the 
resident intestinal microbiota exists in dynamic balance with the host immune system; the 
intestinal epithelium provides an essential barrier that ensures a separate peace between 
host and microbe. However, there is constant crosstalk across this barrier between the 
immune system and microbiota that is equally important for homeostasis in the gut. The 
epithelium, innate and adaptive immune systems, and the intestinal mucus are all active 
participants in host defense from infectious diseases that target the gastrointestinal 
mucosa as their portal to invading their human hosts. Gut bacteria also provide an 
important line of defense for their hosts against invading pathogens, a process known as 
colonization resistance. 
Colonization resistance 
Colonization resistance is the process by which the indigenous gut microbiota 
protects a host from infectious microbes. Several mechanisms underpin colonization 
resistance, the foremost of which is competition for space and nutrients along the mucus 
layer and within the lumen (18). In addition, bacteria employ a number of mechanisms 
for direct competition with their microbial neighbors. Short-chain fatty acids, which are 
products of commensal bacterial metabolism, are also bactericidal for some enteric 
pathogens!(19). Certain Lactobacilli, in particular members of the acidophilus 
subgroup, generate reactive oxygen species that are inhibitory to other bacteria in the 
gastrointestinal tract (20). Numerous commensals produce antimicrobial peptides, called 
bacteriocins, as defensive strategies. Bacteriocins fall into three general categories (I, 
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IIa/b/c, and III) and have distinct activities: nucleases, DNAses, cell wall component (eg, 
peptidoglycan) production inhibitors, and pore formers (21). Studies using mouse models 
suggest that the composition of a host’s microbiota may influence susceptibility to 
enteropathogens (22). Furthermore, particular members of gut microbial communities 
impact the ability of pathogens to invade and beneficial microbes to colonize. Hosts with 
high Escherichia coli densities are more susceptible to Salmonella enterica infection, 
whereas hosts with high Lactobacilli counts are more easily colonized with other 
probiotic strains of Lactobacilli (22).  
As a third mechanism of colonization resistance, bacteria can influence the host’s 
immune system in a way that precludes invasion by pathogens. Presence of bacteria in 
the gastrointestinal tract induces Paneth cells in the small intestine to produce REGIIIγ, 
an antimicrobial peptide that limits invasion of Gram-positive bacteria across the 
epithelial mucus layer (23). Additionally, engagement of host toll like receptors (TLRs) 
by bacterial ligands ultimately leads to IgA production by B cells for defense at the 
mucosal barrier!(24). 
Symbiotic bacteria and the immune response 
Symbiotic enteric bacteria are required for immune cell development and function 
within the gastrointestinal tract and systemically. Studies from germ-free (GF) and 
gnotobiotic mice (mice lacking endogenous microbes) demonstrate abnormal Peyer’s 
patches, lymph nodes, and spleen; decreased numbers of mucosal and systemic innate 
and adaptive immune cells; and markedly reduced levels of immunoglobulins and other 
host defense molecules (25). Susceptibility to numerous bacterial, viral, and parasitic 
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infections is also increased in GF mice, resulting from loss of colonization resistance and 
impaired immune system responses. 
Several studies have identified that select species or specific bacterial products 
play a critical role in the proper functioning of the immune system. Although 
Bacteroides fragilis is well known for its opportunistic role in intraperitoneal abscesses, 
it also bestows benefits to the host regarding the development of adaptive immunity in 
the gut and system-wide. A zwitterionic polysaccharide, polysaccharide A, expressed by 
B. fragilis is responsible for these beneficial effects on host immune cell development 
and homeostasis (26). In addition, polysaccharide A also appears to protect mice from 
experimentally induced inflammatory bowel disease and central nervous system 
inflammation (27,!28). T helper 17 cells (Th17), a subset of CD4+ T cells named for its 
production of the proinflammatory cytokine IL-17, function in host defense against fungi 
and extracellular bacteria and have been implicated in the pathogenesis of numerous 
autoimmune diseases (29). In mice, the induction of intestinal Th17 cells requires that the 
small intestine is colonized with segmented filamentous bacteria (SFB), a group of 
anaerobic, spore-forming, gram-positive bacteria (30). SFB stimulate the expression of 
several genes involved in antimicrobial defenses and inflammation. The bacterial 
molecules, host sensors, and signaling pathways involved in this SFB-mediated Th17 
development remain to be defined. 
Both immune and non-immune system cells express a diverse repertoire of pattern 
recognition receptors that bind molecular patterns shared among microbes. The TLRs are 
one family of pattern recognition receptors. Flagellin, the TLR5 ligand, recently was 
shown to restore innate immune defenses against and decrease colonization levels of 
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vancomycin-resistant Enterococcus (31). The nucleotide-binding domain, leucine rich 
repeat containing proteins, are another family of microbial recognition receptors. 
Nucleotide-binding oligomerization domain protein (NOD) 2 has a broad specificity for 
peptidoglycan and NOD1 senses diaminopimelic acid-type peptidoglycan. Intestinal 
commensal bacterial-derived diaminopimelic acid-type peptidoglycan plays an important 
role in priming systemic innate immunity. Specifically, studies of NOD1-deficient and 
wild-type (WT) mice demonstrated that importance of NOD1 signaling for neutrophil 
killing of Streptococcus pneumoniae and Staphylococcus aureus (32). Thus, humans 
and our ancestors evolved a dual-purpose system for sensing microbes—a system that not 
only senses endogenous microbes for the proper development and functioning of the 
immune system, but also senses pathogenic invaders to initiate host defense programs.  
Antibiotics and the Commensal Microbiota 
Antibiotics can have several disruptive effects on the endogenous flora, the most 
familiar of which are the antibiotic-associated diarrheas. Recent genomic studies of the 
intestinal microbiota, both in human populations and mouse models, have revealed that 
antibiotics have unexpectedly widespread and enduring effects on endogenous gut 
microbes. Duration of treatment, type of antibiotic, and individual differences all 
influence antibiotic-induced changes in the composition of the gut bacterial community 
and the resiliency of gut community members to antibiotic treatment. 16S rDNA 
enumerations from human stool before and 4 weeks after ciprofloxacin treatment 
revealed that although the majority of gut microbes eventually returned to their pre-
treatment relative abundance levels, taxa belonging to the Clostridiales order did not 
recover during the observation period (33). A common theme illuminated by studies of 
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the antibiotic effects on gut microbial composition is a reduction in relative abundance of 
members of the Firmicutes phylum and specifically several Lactobacillus species, many 
of which are considered beneficial microbes (34, 35). Broad-spectrum antibiotic 
treatment of mice revealed large proportional increases in the Bacteroidales order. After 
only 1 day of antibiotics, representation of this order increased to 95%, from basal levels 
of 60% to 70% of the total bacterial population (34). These perturbations have the 
potential to be significant in light of recent studies demonstrating a link between diabetes 
(36) and obesity (4) and decreased gut microbial diversity and altered Bacteroidetes to 
Firmicutes ratios. 
Antibiotic-induced alterations of the composition or function of gut microbial 
communities are key effectors in susceptibility to several gastrointestinal bacterial 
diseases. Antibiotic-associated diarrhea (AAD) is a common complication of antibiotic 
use, and Clostridium difficile is the most frequent cause of AAD, colitis, and 
pseudomembranous colitis (37). Klebsiella oxytoca, Clostridium perfringens, 
Salmonella spp, Candida spp, and Staphylococcus aureus are far less common causes 
of AAD. Both the incidence and death rates of C. difficile–associated colitis have 
increased at an alarming rate over the past decade (117% increase in incidence between 
2000 and 2006 and a 35% increase in mortality rates) (37). Estimates of asymptomatic 
carriage of C. difficile range between 1% and 55.4%, based on the population observed 
(38). A few studies have begun to delve into how the composition of the fecal microbiota 
affects susceptibility and risk of recurrence of C. difficile–associated diarrhea. A 
correlation between C. difficile–associated diarrhea and the extent and duration of 
decreased diversity in response to antibiotics is emerging (38). A recent study by Giel et 
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al. (39) provides mechanistic insight into how antibiotic treatment may result in C. 
difficile sporulation and subsequent AAD. Bile salt metabolism by the commensal 
microbiota appears to be a key effector. A cholestyramine-sensitive factor in cecal or 
intestinal extracts of antibiotic-treated mice stimulated C. difficile colony formation 
from spores much more efficiently than samples from untreated mice (39). 
Antibiotics also increase susceptibility to invading microbes of the 
gastrointestinal tract. Treatment of mice with streptomycin or vancomycin lowered the 
inoculum dose required to cause morbidity with Salmonella enterica Serovar 
Typhimurium (40). The doses of antibiotics used in this study did not reduce total 
bacteria numbers in the gut, a finding emphasizing that composition and function of the 
community are important factors in mediating host resistance to invading pathogens. 
Beyond shifting relative abundances of gut bacteria, antibiotics also have the ability to 
influence the genomic potential and expression of the gut microbial community. 
Treatment with high doses of antibiotics selects for bacteria with antibiotic resistance 
genes on mobile genetic elements. Even though the typical members of the gut microbial 
community may re-colonize the gut over time, horizontal gene transfer of antibiotic 
resistance may irrevocably alter the intestinal microbiota. 
Gut microbiota as reservoirs of resistance 
The existence of lag times between when widespread clinical use of an antibiotic 
begins and when resistance becomes a problem—a few years for penicillin and more than 
30 years for vancomycin (41)—suggests that gut bacteria living without exposure to 
antibiotics do not typically harbor resistance genes. However, bacteria in the soil, an 
ancient antibiotic resistance reservoir, have spent millions of years evolving in the 
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presence of natural antimicrobials, resulting in the expression and spread of many 
resistance genes via horizontal gene transfer (HGT) (42). The gut represents an 
environment that, like soil, is highly conducive for HGT—a dense population of bacterial 
cells, often found organized similar to a biofilm (41). Once in the gut, antibiotic 
resistance genes can disseminate throughout the bacterial population, especially under 
selection pressure from clinically administered antibiotics, and these effects of HGT can 
endure after selection is removed. After combined antibiotic treatment for Helicobacter 
pylori gastritis (with a clarithromycin and metronidazole regimen), gut enterococci 
exhibited high macrolide resistance for 1 year after treatment; for one patient, resistance 
remained even after 3 years (43). A study of the gut microbiotas of two healthy 
individuals with no antibiotic exposure in the preceding year found antibiotic resistance 
genes in both commensal and opportunistic fecal bacteria (44). Almost half of the 
antibiotic resistance genes identified from the sub-cultured fecal isolates were genetically 
identical to antibiotic resistance genes found in known human pathogens (44). Thus, the 
commensal gut microbiome represents a reservoir of antibiotic-resistance genes. Through 
HGT, otherwise harmless commensals have the potential to transfer antibiotic resistance 
determinants to pathogens, which may lead to the emergence of clinically problematic 
strains. 
Viruses and gut bacterial communities 
Viral gastroenteritis 
Viruses are frequently the causative agent of gastroenteritis, one of the most 
common infectious diseases worldwide (45). Specifically, noroviruses were found to be 
responsible for 93% of viral gastroenteritis outbreaks in the United States during a 3-year 
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study period between 1997 and 2000 (46). Although viral gastroenteritis in adults is most 
commonly linked to noroviruses, gastroenteritis in children is caused by a broader group 
of viruses that, along with noroviruses, includes rotaviruses, astroviruses, and sapoviruses 
(47). Both astroviruses and rotaviruses have been shown to directly increase gut mucosal 
permeability (48). Loss of gut barrier integrity alters the delicate balance between the 
immune system and commensal microbiota, and thus compromises defenses against a 
broad range of gastrointestinal pathogens. 
The variable attack rates of enteric viruses bring into question the role of the gut 
microbiota in shaping susceptibility. Undertaking prospective studies of the gut 
microbiota that follow populations over time may illuminate characteristics of microbial 
communities associated with resistance to viral gastroenteritis. Although it is not well 
understood if or how gut microbial populations affect infection with enteric viruses, 
rehydration therapy in conjunction with supplementation with multiple Lactobacilli 
spp. (reuteri, acidophilus, delbrueckii bulgaricus, and casei) and Saccharomyces 
boulardii reduced the duration of rotavirus-associated diarrhea and significantly reduced 
viral shedding (49, 50). Further research into how certain bacteria are able to aid the host 
in clearance of viral infections could be beneficial not only in understanding viral 
pathogenesis, but also in understanding relationships between viruses and bacteria in the 
gut. 
Noroviruses and inflammatory bowel disease susceptibility  
Commensal gut bacteria are important contributors to the pathophysiology of 
inflammatory bowel disease, and evidence suggests that the gastrointestinal microbiota of 
inflammatory bowel disease patients differ from healthy controls (5), with reduced 
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relative abundances of members of the Bacteroidaceae and Lachnospiraceae families 
(51). Recent evidence suggests that the contribution of microbes to inflammatory bowel 
disease extends beyond commensal bacteria to include enteric viruses. About 50% of 
individuals of European descent carry a mutant allele of the autophagy gene Atg16L1, 
which is a Crohn’s disease susceptibility allele (52). A recent study using a mouse model 
with reduced Atg16L1 function begins to explain the contributions of both viruses and 
bacteria to Crohn’s disease susceptibility. Infection with a specific norovirus along with a 
full complement of gut bacteria was required for eliciting Crohn’s disease-like pathology 
after intestinal injury was triggered in mice with reduced Atg16L1 (53). In the absence of 
viral exposure or if the commensal bacteria were depleted with antibiotics, Crohn’s 
disease-like inflammation did not develop, thus demonstrating that a complex web of 
microbial (viral and bacterial) and host factors underlie Crohn’s disease. Although enteric 
viruses may not cause inflammatory bowel disease single-handedly, they have the 
potential to shape the host immune response and intestinal environment in a manner that 
promotes dysfunctional host-commensal interactions. 
Gut bacterial viruses 
Studies of human gut microbiota have revealed that coliphages (enteric bacterial 
viruses) infect many Enterobacteriaceae (E. coli, Salmonella spp, Klebsiella spp) 
and other Bacteroidetes and Firmicutes (54). Despite overwhelming evidence of viral-
bacterial interactions in the human gut, the consequences of such interactions in the 
context of gastrointestinal disease have not been fully explored. Classical phage-bacterial 
host interactions are characterized by an evolutionary struggle for and against viral 
invasion. However, in the fecal microbial community of healthy humans, viral life cycles 
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tend to be temperate (non-lytic) with low variation over time, and with little genomic 
evidence of bacteria evolving mechanisms to prevent phage attachment and invasion 
(55). Enteric phages that are in constant contact with commensal bacteria in the gut have 
the potential to act in a commensal manner of their own and may confer growth 
advantages to their hosts (54). Several viral-like particles found in healthy human feces 
encode proteins involved in peptidoglycan synthesis, pyruvate and folate metabolism, and 
oxidative stress response (55). By introducing new genes and associated functions, 
viruses have the ability to change the microbiome of the gut. In light of recent findings 
that recognize associations between bacteria and human diseases, and between bacteria 
and viruses in the gut, future attention should be focused on the ways in which coliphages 
are able to shape the composition and function of commensal bacterial communities in 
the gastrointestinal tract. 
Inflammatory bowel disease 
Ulcerative colitis and Crohn’s disease are the two main forms of inflammatory 
bowel disease and both are attributed to a combination of an individual’s genetic 
susceptibilities, microbiota, and environment (56, 57).  Ulcerative colitis and Crohn’s 
disease are seen at higher rates in westernized countries and have been linked to factors 
such as stress, diet, medication and socioeconomic status (58).  Despite some similarities, 
ulcerative colitis and Crohn’s disease differ in several significant characteristics.  In 
ulcerative colitis, inflammation occurs exclusively in the colon, while Crohn’s disease 
can present throughout the gastrointestinal tract.  Furthermore, ulcerative colitis and 
Crohn’s disease differ in tissue pathology, genetic susceptibilities and therapeutic 
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treatment approaches (59). Ulcerative colitis has a greater incidence rate than Crohn’s 
disease in the United States (60), with an estimated 15,000 new cases per year (61).  
Currently there are 47 known risk loci associated with ulcerative colitis (62).  
Several mouse models have been used to recapitulate disease (56), including the acute 
dextran sulfate sodium (DSS) model, a sulfated polysaccharide that chemically induces 
barrier damage (63), and IL-10-/- or IL-10R-/- mice (64) that are missing gene products 
necessary for CD4+ T-regulatory cell maintenance of gut homeostasis (65).  In the TRUC 
(T-bet-/- Rag2-/- ulcerative colitis) mouse model (66), Rag2 (recombination activating 2) 
gene deletion leads to the loss of an adaptive immune response through disruption of VDJ 
recombination (67), which is necessary for the generation of B and T lymphocytes.  
Absence of T-bet, a transcription factor important for regulation of innate and adaptive 
proinflammatory responses (68), results in innate immune defects.  In dendritic cells 
(DCs), T-bet binds the promoter of mouse TNFα (tumor-necrosis factor α) to repress 
TNFα transcription (66), and a consequence of T-bet loss is un-regulated production of 
TNFα by bone-marrow derived DCs. 
 
IV. MOUSE MODELS AND MOLECULAR TOOLS USED TO STUDY MICROBIAL 
COMMUNITIES 
 
Gnotobiotic mice and defined microbial communities 
 
Understanding the role that individual bacteria play in the gastrointestinal tract, 
both in terms of host interactions and microbial community relationships, is difficult due 
to the complexity of the microbiota and redundancy in members and function. Tool 
advancements in the form of GF mice have revolutionized the way researchers can study 
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interactions between defined microbial communities and their hosts (69). GF mice are 
bred and maintained inside microisolators in a sterile environment. Modern GF facilities 
use a combination of techniques to ensure sterility of all equipment, food, and supplies 
including chlorine dioxide dunks, autoclaving, and ethylene oxide gas. Absence of 
microbes is confirmed with regular conventional culture and molecular tests on 
equipment swabs and mouse stool. Mouse lines can be derived GF via C-section of SPF 
females, dunking of the uterus into chlorine dioxide, and rearing of pups by a GF foster 
female.  
While GF mice represent an ideal animal model for understanding interactions 
between single microbes and their host, animal development in a sterile environment 
leads to physiological deficiencies. GF mice gain weight more slowly than mice reared in 
the presence of microbes (specified pathogen-free, SPF) and increased calorie intake is 
required to maintain normal weight!(70). These mice have abnormal Peyer’s patches, 
lymph nodes, and spleens and their ceca are markedly larger in size. Development of the 
immune system is also impaired in GF mice with decreased numbers of mucosal and 
systemic immune cells and markedly reduced immunoglobulin-A levels in the colon (25).  
In order to correct some of the defects observed in GF mice while maintaining an 
experimentally tractable microbiome, research groups have turned to the use of 
gnotobiotic mice with specific and defined bacterial inputs. In the 1960’s, Russell 
Schaedler was the first to report colonizing gnotobiotic mice with a defined and reduced 
gut microbiota (71). A variation of the original flora, known commonly as the Altered 
Schaedler Flora (ASF), is used by many investigators to standardize gnotobiotic studies, 
allowing for environmental continuity between facilities and a reduction in community 
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complexity!(72). ASF members are representative of abundant and functionally important 
gut bacteria in the healthy mouse microbiome, and are able to stimulate normal immune 
responses!(73). Specifically, ASF mice show normal IgA secretion into the gut lumen and 
restoration of colonic T-regulatory cell populations. A practical advantage of an ASF 
microbiota is that all strains are culturable under anaerobic conditions.  The ASF include 
the following bacterial species: Clostridium spp. (ASF356), Lactobacillus spp. (ASF360), 
Lactobacillus murinus (ASF361), Mucispirillum schaedleri  
(ASF457), Eubacterium plexicaudatum (ASF492), Firmicutes bacterium (ASF500), 
Clostridium spp. (ASF502), and Parabacteroides spp. (ASF519). 
While the ASF has been used for many years, this community has a noted 
deficiency in Bacteroidetes and Proteobacteria in comparison to the human gut 
microbiota. Recently, groups have begun to refine defined consortia of bacteria for 
gnotobiotic colonization. Jeffrey Gordon and Andrew Goodman developed a defined 
gnotobiotic community composed of 14-bacteria to model the human colon; 6 
Bacteroidetes spp., 7 Firmicutes, and an Actinobacteria (74) (Table 1.1). Koji Atarashi 
and Kenya Honda focused on the Firmicutes, and specifically the class Clostridia, in 
devising a human-derived microbial consortia (75). 
 
16S rRNA gene survey for microbial community assessment 
 One of the biggest challenges of studying mixed microbial communities is 
defining which bacterial species are present. Before the advent of molecular techniques, 
standard culturing methods were needed to ask questions about microbial community 
composition. Despite hundreds of years of optimization of culturing methods, it is widely 
estimated that 99% of bacteria in a given environment remain unculturable. For the gut  
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Table 1.1. Defined microbial communities used in gnotobiotic mouse studies. 
 ASF Goodman/Cordon 
Consortium  
Clostridia cocktail 
Representing Mouse gut 
microbiome 
Human gut microbiome Human Clostridia 
compartment 
Firmicutes Clostridium spp 
Lactobacillus spp 
Lactobacillus 
murinus 
Eubacterium 
plexicaudatum 
Firmicutes bacterium 
Clostridium spp 
Ruminococcus obeum 
Eubacterium rectale 
Dorea longicatena 
Clostridium symbiosum 
Clostridium spiroforme 
Clostridium scindens 
Ruminococcus torques 
Clostridium asparagiforme 
Anaerotruncus colihominis 
Clostridiaceae JC13 
Clostridium bolteae 
Clostridiales 1_7_47FAA 
Lachnospiraceae 7 1 58FAA 
Clostridium scindens 
Clostridium 7 3 54FAA 
Ruminococcus sp. ID8 
Clostridium indolis 
Eubacterium fissicatena 
Clostridium ramosum 
Lachnospiraceae 
3_1_57FAA (2 isolates) 
Clostridium sp. 14774 
Blautia producta 
Clostridium hathewayi 
Bacteroidetes Parabacteroides spp Parabacteroides 
distasonis  
Bacteroides WH2 
Bacteroides vulgatus 
Bacteroides uniformis 
Bacteroides 
thetaiotamicron 
Bacteroides ovatus 
Bacteroides caccae 
None 
Proteobacteria None None None 
Actinobacteria None Collinsella aerofaciens None 
Deferribacteres Mucispirillum 
schaedleri 
None None 
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microbiome, this number greatly decreases to 10% unculturability when anaerobic 
culturing techniques are combined with passage of human fecal communities through 
gnotobiotic mice (76), but the cost and time required for this dual approach can be 
prohibitive. In vitro culturing alone leaves 55% of species unclulturable. 
 In 1991 work from Norman Pace and colleagues demonstrated that PCR cloning 
and sequencing of the bacterial 16S ribosomal RNA (16S rRNA) gene from DNA 
extracted from bulk environmental samples could reveal phylogenetic diversity of mixed 
bacterial communities (77). The discriminative power of this approach is two-fold. First, 
ribosomal building blocks differ between Prokaryotes and Eukaryotes, allowing for 
selective amplification of conserved bacterial sequences in samples with Eukaryotic 
contamination, a principle pioneered by Carl Woese in 1977 (78). Second, the 16S rRNA 
component of the Prokaryotic 30S ribosomal subunit contains regions of discriminately 
significant variability between bacterial species (79). For analysis of bacterial community 
membership, PCR primers are designed to recognize a conserved region of the 16S rRNA 
gene and amplify across one or more of the nine hypervariable and discriminative 
regions. Depending on the hypervariable regions amplified, this approach can reveal 
genus level identification for all sequence reads within certain populations, and 
identification to the species level for a subset of sequences (79). 
 The sequencing technologies and platforms that have been used for 16S rRNA 
surveys are summarized in Table 1.2. Illumina, Life Technologies, and Roche all 
manufacture high throughput and benchtop machines that differ in read length, run 
capacity, and molecular technologies. While most early 16S surveys were performed 
using Roche’s 454 Pyrosequencing platform, Illumina machines have captured the 
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majority market share in recent years due to their lower run costs, high accuracy, and 
large amount of data generated (80). Moving forward, Illumina machines will continue to 
gain market usage as Roche phases their 454 platform out of production. 
 
Table 1.2. Sequencing technologies and platforms used for 16S rRNA amplicon surveys. 
Company 
Sequencing 
Platform Technology Details Notes 
Illumina 
HiSeq (high 
throughput) __ 
Has generated 90% of the 
world’s high throughput 
sequenced genetic material 
MiSeq 
(benchtop) 
Read length: 300bp 
GB per run: 15 
Reads per run: 30M 
>50% market share in bench 
top sequencers; first FDA 
approved sequencing machine 
Life 
Technologies 
Ion Torrent 
PGM 
(benchtop) 
Read length: 400bp 
GB per run: 2 
Reads per run: 5M 
FDA approved sequencing 
machine 
Ion Proton 
(benchtop) 
Semiconductor chips to detect 
protons given off during nucleotide 
addition 
__ 
SOLiD (high 
throughput) Sequencing by ligation Overtaken by Illumina HiSeq 
Roche 
454 
Pyrosequencing Long read 
Being phased out- production 
will stop by the end of 2015 
GS FLX 
(benchtop) 
Read length: 700bp 
GB per run: 0.07 
Reads per run: 0.1M 
__ 
 
Computation tools for analysis of 16S rRNA amplicons  
 Depending on sequencing depth, 16S rRNA surveys can generate tens of 
thousands of reads per sample. Many computational analysis tools have been developed 
for processing and analyzing these large sequence datasets including QIIME 
(Quantitative Insights Into Microbial Ecology) to process sequences (81), PICRUSt 
(Phylogenetic Investigation of Communities by Reconstruction of Unobserved States) to 
predict metagenome and function from 16S sequences (82), and LefSe (Linear 
discriminant analysis Effect Size) to identify operational taxonomic units that are most 
likely to explain differences between classes (83). These tools have aided in a greater 
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understanding of microbial community membership and function across a diverse range 
of environments. 
 
V. KLEBSIELLA PNEUMONIAE EPIDEMIOLOGY, TAXONOMY, AND ENVIRONMENTS 
!
Klebsiella pneumoniae is a rod-shaped, Gram-negative species of Proteobacteria 
from the family Enterobacteriaceae. K. pneumoniae is a facultative anaerobe that was 
first observed by Edwin Klebs in 1875, and officially described in 1882 by Carl 
Friedlander as a bacterial cause of pneumonia (84). Since then, K. pneumoniae has been 
isolated from a diverse array of environments including water, soil, plants, and mucosal 
surfaces of mammals such as the skin, nasopharynx, lungs, mouth, urinary tract, and 
gastrointestinal (GI) tract (85). In the soil and in association with plants, K. pneumoniae 
is considered a plant growth promoting bacteria due to it’s ability to fix nitrogen for 
uptake by plant roots (86). Conversely, K. pneumoniae is considered an opportunistic 
pathogen when associated with human hosts and is a common cause of pneumonia, 
urinary tract infections, bacteremia, liver abscesses and nosocomial infections (87).  
K. pneumoniae virulence factors 
K. pneumoniae has classically been studied from the context of virulence given 
this bacterium’s role in disease. Several factors have been identified as virulence factors 
that aide in K. pneumoniae’s colonization of the host and evasion of immune defenses. 
These virulence factors include lipopolysaccharides (LPS), capsular polysaccharides 
(CPS), fimbriae, and siderophores (85). 
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LPS 
 
LPS is common feature of Gram-negative bacteria and is the layer of extracellular 
polysaccharides anchored in the bacterial outer membrane by lipid A. A core 
oligosaccharide is covalently bound to lipid A on one side and the O-antigen on the other 
(88). Also known as endotoxin, LPS is a microbe-associated molecular pattern (MAMP) 
that is bound by toll-like receptor 4 (TLR4) on host immune cells including monocytes, 
dendritic cells, and macrophages. LPS can initiate a pro-inflammatory cascade and fever 
in mammalian hosts (89).  
 
CPS 
 
In addition to LPS, K. pneumoniae has another layer of extracellular 
polysaccharides known as CPS, or capsule. Over 80 capsule serotypes have been 
identified from K. pneumoniae isolates with several displaying increased virulence. 
Capsule serotypes K1 and K2 are especially virulent and cause severe liver abscesses in 
diabetic and immune compromised patients (90, 91). K. pneumoniae capsule consists of 
glucose, glucuronic acid, and 1 to 4 variable sugars (92). Variable sugars found within K. 
pneumoniae capsule include, mannose, rhamnose, and fucose (93). The presence of a 
capsule has been shown to protect K. pneumoniae from phagocytosis and complement 
opsonization, allowing evasion of the host’s immune system (94). Non-mucoid variants 
(NMVs) of K. pneumoniae, which have reduced production of CPS, have been observed 
at low frequency in vitro (95) and at least once in vivo from a patient with a urinary tract 
infection (96). However, a role for these K. pneumoniae NMVs has not been defined in 
vivo. Since the majority of K. pneumoniae isolates recovered from both infected and 
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healthy humans are mucoid, there are likely advantages to capsule production outside of a 
virulence context. 
K. pneumoniae capsule is encoded on single copy loci within the bacterial 
chromosome that ranges from 16-25 ORFs (93). The K. pneumoniae CPS locus is divided 
into three regions. Starting at the 5’ end are a group of conserved genes, including galF, 
orf2, wzi- an outer membrane protein, wza- which forms a multimeric translocation 
channel, and wzc- a tyrosine autokinase. Protein products of these genes are involved in 
capsule polymer translocation from the inner membrane to the outer membrane. 6-10 
isolate specific glycosyltransferases lie in the middle of the loci, along with the conserved 
glycosyltransferases wbaP and wcaJ. WbaP and wcaJ are responsible for transfer of 
sugar nucleotides to lipid receptors (97). Serotype specific glycosyltransferases are 
thought to connect repeating nucleotide sugar subunits to each other (97) and are a major 
source of variation between the many K. pneumoniae serotypes (93), although the exact 
role that each glycosyltransferase plays in capsule synthesis is undefined for K. 
pneumoniae. On the 3’ end of the capsule loci are a set of genes whose protein products 
participate in modification of the nucleotide linked sugars. Conserved genes in this region 
include ugd and uge, which are involved in the synthesis of UDP-glucuronic acid from 
UDP-glucose (98). Variable genes in this region could include manC/B for synthesis of 
GDP-D-mannose, or rmlA/C/D for synthesis of dTDP-L-rhamnose (99).   
Regulation of capsule production is complex and incompletely defined. Several 
master transcriptional regulators have been shown to influence CPS production in K. 
pneumoniae, including Fur. Fur activates CPS synthesis in environments with ample iron 
and represses synthesis in times of iron stress (100). In addition to Fur, K. pneumoniae 
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CPS production is also regulated by RcsBCD, a two-component phosphorylation cascade 
that leads to transcriptional activation at the CPS promoter in response to environmental 
stimuli. The RcsBCD two-component system can also be activated by RmpA, the protein 
product of rmpA, which is carried on the 180-kb virulence plasmid, pKP100 (101). 
Plasmid pKP100 is typically found in isolates of the virulent K1 and K2 serotypes. A 
second virulence plasmid, pLVPK contains both rmpA and rmpA2. RmpA2 is a 
transcriptional activator of the LuxR family and can bind with RcsB or directly to the 
CPS promoter to stimulate capsule production (101). While diverse capsule regulation 
mechanisms have been detailed, it is not clear how these multiple inputs are integrated by 
K. pneumoniae. 
 
Fimbriae 
 
 K. pneumoniae are non-motile and lack flagella. However, they do have fimbriae, 
projections composed of curlin protein, extending from their outer membrane. These 
projections measure approximately 4.2 nanometers in diameter and 1.5um in length 
(102). Fimbriae contain adhesins that aide in the attachment of bacteria to each other and 
to host cells. Two fimbriae types have been observed in the K. pneumoniae genus, type 1 
and type 3 (103). Type 1 fimbriae have been identified in many species of 
Enterobacteriaceae and are used by bacteria to adhere to the urogenital epithelium in a 
mannose dependent manner (104). Type 3 fimbriae have been found to agglutinate 
erythrocytes, are thought to play an important role in biofilm formation, and are mannose 
insensitive (105). 
 The presence of a capsule impedes the ability of fimbriae to adhere to neighboring 
cells. Several reports suggest that fimbriae and capsule may be opositionally regulated 
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and coordinated to both the anatomical location and stage of infection (106). Fimbriae are 
especially important in establishing urinary tract infections, but do not influence K. 
pneumoniae’s ability to colonize the gastrointestinal tract or nasopharynx (107).  
  
 
 
Siderophores   
 
 While essential for bacterial growth, iron is limited under normal conditions in 
mammalian hosts and sequestered by host proteins including hemoglobin, transferrin, 
lactoferrin, and ferritin. For this reason, many bacteria produce siderophores- compounds 
with a strong affinity for iron that are released by bacteria and taken back up after they 
have acquired ferric iron and formed soluble Fe3+ compounds (108). K. pneumoniae 
produces several known siderophores, the most common being enterobactin (109). 
Hypervirulent isolates have been found to produce additional siderophores including 
yersiniabactin, salmochelin, and aerobactein. Aerobactin is particulary important in 
supporting both ex vivo growth and virulence of hypervirulent K. pneumoniae (110). 
Klebsiella genome and plasmids 
The advent of whole genome sequencing and analysis tools has significantly 
contributed to an understanding of genome structure and diversity with the K. 
pneumoniae species. On average, the K. pneumoniae genome is 5.3 mega base pairs. Of 
the 5,705 genes per genome (median), 1,743 are conserved across 328 isolates and are 
considered part of the core K. pneumoniae genome (111). Much of the large accessory 
genome shows evidence of acquisition through horizontal gene transfer due to altered 
G+C content relative to the core genome. These transfer events likely occurred with other 
bacterial species such as Vibrio and Acinetobacter (111). 
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Comparative genomics pipelines have been used to identify strain based virulence 
determinants in K. pneumoniae strains (112). A popular tool for comparative genomics is 
OrthoMCL(113), a graph-based Markov-clustering algorithm that allows parsing of 
proteomes into protein groups representing orthologs, paralogs and co-orthologs. A 
comparative genomics analysis of K. pneumoniae plasmids revealed similarities across 
isolate types that suggest a strong role for horizontal gene transfer in the genomic 
evolution of the species!(114). Many of K. pneumoiae’s plasmids carry important 
virulence determinants, including the previously mentioned plasmids pkP100 and 
pLVPK, which are involved in regulation of capsule production. 
Antibiotic resistance of K. pneumoniae  
 Antibiotic resistant K. pneumoniae represents a large and recent threat to human 
health. The first K. pneumoniae isolate with resistance to a broad range of antibiotics was 
discovered in 1996 in a patient from North Carolina (115). This isolate produced 
Klebsiella pneumoniae carbapenemase (KPC), conferring weak resistance to 
carbapenems, which are beta lactam antibiotics widely used to treat bacterial infections. 
Enterobacteriaceae carrying plasmid-encoded New Delhi metallo-β-lactamase 1 (NDM-
1) were later observed in 2010 in Taiwan (116). Unlike KPC, NDM-1 producing K. 
pneumoniae are strongly resistant to carbapenems. While Asian countries remain the 
hotbed of NDM-1 producing isolates (top three: Indonesia, Vietnam, and Philippines), 
resistance has spread rapidly world-wide and infections are now reported throughout 
North America, South America, and Europe.  
While carbapenem resistance can be transferred between and among many species 
of Enterobacteriaceae, K. pneumoniae represents the largest reservoir and accounts for 
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39% of carbapenem-resistant Enterobacteriaceae in Asia, followed by E. coli with 22% 
(117). In 2013, the US Centers for Disease Control classified carbapenem-resistant K. 
pneumoniae as an urgent threat, giving it the highest threat level amongst drug-resistant 
bacteria (115). Recent epidemiology studies suggest an incidence rate of carbapenem-
resistant K. pneumoniae infections in 2.93 out of 100,000 people in the US (118) and 
clusters of infections are beginning to manifest in clinical settings. In the most well 
documented outbreak in the US, 18 infections and 6 deaths were attributed to 
carbapenem-resistant K. pneumoniae at the US National Institutes of Health Clinical 
Center (119). Genomic comparisons from infected patients suggested a single patient 
origin with 3 independent transmission events between patients. Complicating 
transmission of antibiotic resistant K. pneumoniae further is the fact that this bacteria is 
carried by healthy humans in the gastrointestinal tract. Recently it was found that gut 
colonization by KPC producing K. pneumoniae is a risk factor with an odds ratio of 13.33 
for mortality in diabetic patients with foot infections (120). 
K. pneumoniae in the gastrointestinal tract 
An estimated 5-38% of the general population carries K. pneumoniae in their 
gastrointestinal tract and these numbers increase in hospital settings where up to 77% of 
caregivers and patients are K. pneumoniae positive (85). Regions of East Asia, such as 
Taiwan, also report these higher GI carriage rates in healthy populations (121). 
Epidemiological work following diabetic patients with liver abscesses and foot infections 
suggest that GI carriage predisposes people to infection and serves as a general reservoir 
for K. pneumoniae disease (122, 120). Similarly, gut colonization by K. pneumoniae has 
been shown to precede bloodstream infections in patients undergoing stem cell 
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transplantation (123). While K. pneumoniae has not been implicated in driving 
inflammatory bowel disease or other infections in the gastrointestinal tract, patients with 
Crohn’s disease have high antibody responses against K pneumoniae (124).  
Signature tagged mutagenesis identified several genes that are necessary for 
colonization of the gastrointestinal tract by K. pneumoniae (125). Of particular 
importance are genes involved in metabolism, including glucose and nitrogen metabolism 
and urea utilization. Mutation of an uncharacterized adhesion attenuates both 
colonization and attachment to human epithelial cells in vitro (125). In mice, K. 
pneumoniae can be found in increasing numbers descending the small intestine and into 
the colon (126). Regardless of intestinal geography, K. pneumoniae is most abundant in 
the luminal content adjacent to the intestinal epithelium (126). 
Gaps in understanding and rationale for this work 
 A murine isolate of K. pneumoniae is able to drive colonic inflammation in mice 
(127), but a role for this bacterium in driving inflammatory bowel disease in humans is 
undefined. Chapter 2 details our aim to further investigate the inflammatory potential of 
K. pneumoniae in the gastrointestinal tract with a diverse panel of murine and human 
clinical isolates.    
In addition, while several studies have attempted to define K. pneumoniae 
colonization factors in the gastrointestinal tract, screens have not been saturating and the 
role of bacterial competition with other members of the microbiome have been 
overlooked. For example, there have been contradictory data on the role of capsule when 
K. pneumoniae colonizes the gastrointestinal tract (128-130). Most recently, encapsulated 
K. pneumoniae and mutants with decreased capsule production were found to have 
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equivalent gastrointestinal colonization levels as measured by fecal bacterial counts in 
streptomycin treated mice (129). Streptomycin treated mice harbor a microbiota reduced 
in complexity and diversity, presenting less colonization resistance than a healthy 
microbiota. This suggests that capsule may play a role in successful and competitive 
interactions with other bacteria in the gut. Chapter 3 investigates the role of both host 
factors and bacterial competition on capsule population dynamics of K. pneumoniae 
throughout the gastrointestinal tract. 
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CHAPTER 2 
!
KLEBSIELLA PNEUMONIAE AND DISEASE: ASSESSING STRAIN-DEPENDENT 
VIRULENCE AND DEFINING THE MINIMAL MICROBIAL COMMUNITY 
NECESSARY FOR DISEASE INDUCTION 
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I. ATTRIBUTIONS 
Leslie Wardwell-Scott performed all experiments and analyses, except as follows: the 
Klebseilla sequencing group at the Broad Institute performed whole genome sequencing 
of K. pneumoniae strains. Qiandong Zeng of the Broad Institute annotated whole 
genomes. Comparative genomic analyses (Figure 2.5, 2.5) were performed in 
collaboration with Ashlee Earl and Abigail McGuire of the Broad Institute. 16S rRNA 
amplicon sequencing was undertaken by Research and Testing in Lubbock, Texas 
(Figures 2.7, 2.8). Tissue samples were sectioned and stained by the Histopathology 
Core at Harvard Medical School and sections were analyzed for inflammation by 
pathologists Jonathan Glickman and Roderick Bronson (Figure 2.2). 
 
II. ABSTRACT 
Klebsiella pneumoniae is an opportunistic pathogen that causes several human 
diseases including pneumonia, urinary tract infections, bacteremia, and liver abscesses. 
There is a high degree of genetic diversity within the K. pneumoniae species, and many 
of these differences relate to an isolate’s virulence potential in certain infection models. 
In this chapter, we characterized four isolates of K. pneumoniae taken from both mouse 
and human host environments. Whole genome sequencing and comparative genomics 
revealed genome level differences in K. pneumoniae depending on host organism (human 
or mouse) and host anatomical location (stool, sputum, or urine).  
 To assess the role of intra-species genomic diversity on interactions with the host, 
these K. pneumoniae isolates were studied in the T-bet-/- Rag2-/- and dextran sodium 
sulfate models of ulcerative colitis and in a mouse model of systemic neonatal infection. 
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Despite genome diversity, K. pneumoniae isolates did not differ in their ability to 
stimulate colonic inflammation. Additionally, K. pneumoniae was unable to drive 
ulcerative colitis in germ-free mice or in gnotobiotic mice stably colonized with 8 
bacterial species, suggesting importance of a full microbiota for K. pneumoniae driven 
virulence in the gastrointestinal tract. 
While there was no differential virulence of K. pneumoniae isolates in the adult 
mouse colon, exposure to murine K. pneumoniae, but not human clinical isolates, led to 
neonatal death. In addition, this isolate induced differential shifts in levels of other 
Enterobacteriaceae species in the colon. More murine K. pneumoniae was found in host 
mesenteric lymph nodes compared to human isolates, suggesting subtle strain-based 
differences that affect response to K. pneumoniae in the gastrointestinal tract.!
!
!
III. INTRODUCTION 
The recovery of K. pneumoniae from many environmental and host sites suggests 
a significant degree of diversity within the species. For example, the genomic content 
necessary for successful colonization of the gastrointestinal tract is likely to be distinct 
from functions necessary for bacterial interactions and nitrogen fixing abilities in the 
plant rhizosphere. Many studies have attempted to reveal genome level K. pneumoniae 
strain-based differences with the use of unbiased comparative genomic approaches (111, 
112, 131). Hybridization techniques comparing 15 clinical K. pneumoniae strains 
identified genomic signatures of putative virulence factors that correlated with severity of 
infection in vivo (112). In the largest K. pneumoniae comparative genomics endeavor to 
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date, analysis of 288 strains revealed such a high level of diversity that the species could 
be divided into three distinct phylotypes (111). 
While comparative genomics has revealed strain based virulence determinants in 
liver abscess and meningitis causing K. pneumoniae strains (112), comparative virulence 
potential has not been assessed in models of ulcerative colitis or neonatal infection. In 
this work we interrogate the role of K. pneumoniae isolated from inflamed T-bet-/- Rag2-/- 
mice in the context of ulcerative colitis and neonatal infection with comparative 
genomics of 4 K. pneumoniae isolates taken from diverse host environments. In vivo 
differential virulence studies were conducted using T-bet-/- Rag2-/- and Rag2-/- mouse 
models of ulcerative colitis and neonatal infection. 
Necrotizing enterocolitis (NEC) is a gastrointestinal disorder affecting preterm 
infants and causing death in 16-42% of those afflicted (132). Inflammation is thought to 
result following translocation of intestinal bacteria across the epithelium in preterm 
infants with an underdeveloped gastrointestinal tract and compromised mucosal 
immunity (133, 134). K. pneumoniae has been associated with NEC in human infants 
(135) and is also known to drive NEC-like intestinal inflammation in neonatal mouse 
models (136).  In this work we devise a model of neonatal infection mimicking the 
underdeveloped immune system of preterm infants by inoculating Rag2-/- pups at birth. 
To study gastrointestinal inflammation in adult mice, we employed the T-bet-/- 
Rag2-/- mouse model, which is an applicable tool for studying ulcerative colitis due to its 
high disease penetrance and features resembling human ulcerative colitis, such as mono- 
and polymophonuclear cell infiltrates of the lamina propria, neutrophil infiltration of 
crypts, and epithelial injury restricted to the colon!(66).  Furthermore, increased colonic 
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tumor necrosis factor α (TNFα) levels are typical of human and T-bet-/- Rag2-/- colitis and 
both forms of the disease can be ameliorated by anti-TNFα therapy. In T-bet-/- Rag2-/- 
mice, increased TNFα is driven by the absence of T-bet, which normally acts as a 
transcriptional activator of cytokine expression. 
 Another similarity between T-bet-/- Rag2-/- and human ulcerative colitis is the 
importance of bacteria in perpetuating aberrant immune responses. Conventional culture 
from stool identified 7 bacterial strains unique to T-bet-/- Rag2-/- compared to Rag2-/- and 
wild-type (WT) mice!(127). Of these seven, K. pneumoniae and Proteus mirabilis 
showed identical sensitivity profiles to antibiotics able to ameliorate colitis in vivo. K. 
pneumoniae and P. mirabilis, individually and in combination, were able to induce colitis 
in Rag2-/- and WT mice (127). Although to date no published studies link K. pneumoniae 
to human ulcerative colitis, subsets of patients with Crohn’s disease show increased 
antibody responses against K. pneumoniae compared to healthy controls!(124), and 16S 
profiling from biopsies of Crohn’s disease patients indicate the presence of K. 
pneumoniae!(137). While not specifically focused on ulcerative colitis, these studies 
justify examining K. pneumoniae in the setting of inflammatory bowel disease. 
Although able to colonize the colon, a combination of K. pneumoniae and P. 
mirabilis is unable to cause colitis in gnotobiotic T-bet-/- Rag2-/- mice!(127), highlighting 
the importance of interactions between these Enterobacteriaceae, other resident members 
of the microbiota, and the host immune system. Based on reports suggesting that 
gnotobiotic mice associated with the Altered Schaedler Flora (ASF) display active 
immune responses!(73), we hypothesized that a combination of ASF strains plus K. 
pneumoniae and P. mirabilis would cause colitis in gnotobiotic T-bet-/- Rag2-/-  mice.  
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Alternatively, the ASF may represent too minimalistic a gut microbiota, and other 
features not represented in this consortium may be needed for K. pneumoniae and P. 
mirabilis to induce inflammation. 
   
IV. RESULTS 
K. pneumoniae isolates do not vary in their ability to incite inflammation in the 
colons of specified pathogen-free Rag2-/- mice. 
 
K. pneumoniae is enriched in the gastrointestinal tract of TRUC mice compared to 
Rag2-/- and WT mice (127). However, when K. pneumoniae WGLW5, isolated from T-
bet-/- Rag2-/- mice, is fed regularly to specified pathogen-free (SPF) Rag2-/- and WT mice, 
colitis develops (127). In order to assess the contribution of K. pneumoniae to colonic 
inflammation, we obtained three human clinical isolates of K. pneumoniae taken from 
patient urine, sputum, and stool (three independent patients). All patients were sick at 
time of culture. Culture of K. pneumoniae WGLW5 and these three human clinical 
isolates on MacConkey agar revealed a shared mucoid phenotype with varying degrees of 
mucoviscosity as assessed by the sting test (138) (Figure 2.1). Hypermucoviscosity is 
defined by the formation of a viscous capsule string, at least 10mm in length, when a 
bacteriological loop is lifted away from a colony on agar (139). While all four isolates 
produced a thick, visible capsule, WGLW2 was the only isolate that did not display a 
hypermucoviscosity capsule phenotype. WGLW5 consistently produced the longest 
string throughout all experiments and manipulations.  
K. pneumoniae isolates resuspended in PBS were fed from pipette tips to 4-week 
old SPF Rag2-/- mice every third day for 8 weeks (Figure 2.2A). Upon sacrifice, colons 
were fixed in paraformaldehyde, paraffin embedded, sectioned, and stained with  
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Figure 2.1.  Mouse and human clinical K. pneumoniae isolates on MacConkey agar. 
Overnight growth at 37°C. Right panel, string test showing hypermucoviscosity phenotype 
(arrows). 
WGLW1
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Figure 2.2.  K. pneumoniae isolates do not significantly differ in their ability to initiate 
colonic inflammation. (A) Experimental schema for K. pneumoniae feeding of SPF Rag2-/- mice.  
Beginning at 4-weeks of age, mice were fed 1.5x108 CFU K. pneumoniae isolate in 25 µl PBS 
every third day for 8 weeks.  Mice were sacrificed and colons were processed for histology on 
day 56. (B) Cumulative colitis score for mice fed K. pneumoniae isolates.  0-3 score each for 
crypt hyperplasia, mononuclear cell infiltrates, polymorphonuclear cell infiltrates, and epithelial 
injury. Each group n=10.  No significant difference between groups, Mann-Whitney test. (C) 
Edema score for a random subset of mice in (B). No significant difference between groups, 
Mann-Whitney test. TRUC is K. pneumoniae WGLW5. 
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hematoxylin and eosin. Two independent pathology score systems revealed no significant 
differences in colitis metrics between mice fed any of the 4 K. pneumoniae isolates or an 
E. coli control (Figure 2.2B and C). 
Differential virulence of K. pneumoniae in a mouse model of neonatal infection.  
In order to assess the virulence of K. pneumoniae isolates outside of the 
gastrointestinal tract, we devised a systemic neonatal infection model. Rag2-/- pups were 
cutaneously inoculated close to the mouth (termed “sprinkled”) with 1.3x108 CFU K. 
pneumoniae isolates in 20 μl PBS daily for 8 days beginning on the day of birth.  Pups 
sprinkled with human stool, sputum, or urine K. pneumoniae isolates displayed 100% 
survival over the course of the experiment. In contrast, pups sprinkled with K. 
pneumoniae WGLW5 had a 30% mortality rate (Figure 2.3A). To confirm spread of K. 
pneumoniae beyond the gastrointestinal and genitourinary tracts, spleens and livers were 
aseptically removed from three pups undergoing K. pneumoniae WGLW5 sprinkling.  
One of the pups had been dead for less than 4 hours. The other two pups were littermates- 
one appeared sickly in movement, color, and growth while the other appeared healthy. As 
expected, the healthy pup had 100-fold lower K. pneumoniae counts in the spleen and 20-
fold lower counts in the liver as compared to sickly and dead pups, confirming the 
presence of systemic K. pneumoniae infection driven by neonatal sprinkling of bacteria 
(Figure 2.3B). 
Pups surviving early life K. pneumoniae inoculation (Figure 2.3A) were assessed 
for stable K. pneumoniae gastrointestinal colonization 7-weeks after their final K. 
pneumoniae exposure. While all K. pneumoniae isolates stably colonized the 
gastrointestinal tract of these mice, only K. pneumoniae WGLW5 sprinkling led to a  
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Figure 2.3.  TRUC K. pneumoniae WGLW5 induces systemic neonatal infection and stably 
colonizes survivors. (A) Survival curve of Rag2-/- pups sprinkled daily with 1.3x108 CFU K. 
pneumoniae isolate in 20 µl PBS.  K. pneumoniae WGLW5 n=12, human sputum K. pneumoniae 
n=7, human stool K. pneumoniae n=5, human urine K. pneumoniae n=10. (B) K. pneumoniae 
CFU counts were assessed from the spleen and liver of K. pneumoniae WGLW5 sprinkled pups. 
Left- pup dead for less than 4 hours, middle- a sickly pup, and right- its healthy littermate. (C) 
CFU counts of K. pneumoniae and P. mirabilis from stool of 2-month old pups that survived the 
K. pneumoniae sprinkling in (A). (D) K. pneumoniae load in the mesenteric lymph nodes of 2-
month old pups in (C) as assessed by K. pneumoniae 23S expression relative to total 16S 
(QPCR). Mann-Whitney statistical test, * P≤0.05. ** P≤0.01. TRUC is K. pneumoniae WGLW5. 
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concurrent colonic bloom of P. mirabilis as measured by CFU counts on MacConkey 
agar (Figure 2.3C), suggesting strain based differences between mouse and human 
derived isolates of the same bacterial species, with the caveat of small samples sizes of K. 
pneumoniae isolates in these experiments. In addition, only K. pneumoniae WGLW5 
sprinkled mice had detectable levels of K. pneumoniae in their mesenteric lymph nodes 
by real-time quantitative PCR (Figure 2.3D). 
Comparative genomics of K. pneumoniae isolates reveals genome level differences. 
 Based on the differential virulence capacity of K. pneumoniae WGLW5 in the 
neonatal infection model and long-term gastrointestinal colonization dynamics compared 
to human clinical isolates (Figure 2.3), we sought to assess the genomic diversity 
amongst K. pneumoniae strains. Whole genome sequences were generated for our 4 K. 
pneumoniae isolates on an Illumina MiSeq by the Broad Institute through the Klebsiella 
group Sequencing Project. Genomes were annotated with Prodigal (140). For comparison 
to a broad range of K. pneumoniae isolates, 5 published genomes were re-annotated with 
Prodigal. The final group of K. pneumoniae genomes consisted of 7 human isolates, an 
environmental isolate, and a mouse isolate (Table 2.1). Genome size fell between 5.33 
and 5.92 Mb, corresponding to 5,069 - 5,448 predicted genes (Table 2.1). 
Following annotation, genomes were translated to proteomes and matched to 
protein databases using BLASTP (http://blast.ncbi.nlm.nih.gov). OrthoMCL, a graph-
based Markov-clustering algorithm (113), was then used to parse proteomes into protein 
groups representing orthologs, paralogs, and co-orthologs (141). By default, proteins that 
did not fall into clusters of orthologs represented the auxiliary genome of each K. 
pneumoniae isolate. Based upon the presence and absence of predicted proteins called by 
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Table 2.1. K. pneumoniae genome details for comparative genomics study. 
K. pneumoniae 
Genome 
 
Source Site 
 
Location 
 
Size (Mb) 
 
GC% 
Predicted 
Genes (#) 
WGLW1 human urine Boston, MA 5.55 57.3 5,170 
WGLW2 human sputum Boston, MA 5.75 56.9 5,292 
WGLW3 human stool Boston, MA 5.55 57.3 5,159 
WGLW5 TRUC stool Boston, MA 5.82 56.8 5,448 
342 Zea mays root UK 5.92 56.9 5,936 
HS11286 human sputum China 5.33 57.5 5,404 
NTUH-K2044 human liver abscess Taiwan 5.47 57.4 5,386 
1084 human liver abscess Taiwan 5.39 57.4 5.069 
MGH78578 human sputum Boston, MA 5.69 57.2 5,305 
 
orthoMCL, a heatmap was constructed to visualize relationships between isolates (Figure 
2.4A). Unexpectedly, K. pneumoniae WGLW5 was most closely related to human 
sputum isolates, and more distantly related to those from stool or urine. An independent 
maximum likelihood phylogeny tool, RAxML (Randomized Axelerated Maximum 
Likelihood (142)), confirmed the relationship between WGLW5 and human sputum K. 
pneumoniae (Figure 2.4B).  
OrthoMCL revealed that the majority of predicted proteins were shared by 
K.pneumoniae isolates from diverse environments (core proteome in blue, Figure 2.5). K. 
pneumoniae WGLW5 had the largest auxiliary proteome with 886 non-core proteins and 
445 unique predicted proteins. Venny (http://omictools.com/venny-s6319.html) was used 
to compare orthoMCL clusters between K. pneumoniae WGLW5 and the 3 human 
clinical isolates from Figure 2.2 and 2.3. This analysis revealed 74 proteins with 
annotated KEGG gene pathways or Pfam protein domains that were unique to K. 
pneumoniae WGLW5 and 44 unique to the human clinical isolates (Table 2.2). Included 
among the cluster unique to WGLW5 were proteins involved in conjugation, toxin anti-
toxin systems, phage, heavy metal resistance, secretion systems, and metabolism. The 
presence of genes encoding these predicted proteins may contribute to the differential 
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Figure 2.4.  Relationships between 9 K. pneumoniae isolates based on comparative genomics 
from whole genome sequence. (A) Heatmap and relatedness tree based on predicted protein 
presence and absence parsed via orthoMCL. Blue lines denote protein presence; black lines 
represent protein absence. (B) RAxML phylogenetic tree of 9 K. pneumoniae isolates anchored 
by an E. cloacae genome. 
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virulence and gastrointestinal colonization potential observed for K. pneumoniae 
WGLW5 in comparison to human clinical isolates in specified pathogen-free (SPF) 
mouse models. It is also likely that the 494 predicted hypothetical proteins unique to 
TRUC contribute to these behaviors. Further analysis of these uncharacterized proteins is 
necessary to fully understand the unique activity of K. pneumoniae WGLW5 in mouse 
models. 
 
                         
 Figure 2.5. OrthoMCL gene clusters of 9 K. pneumoniae isolates.  Core genome in blue, 
auxiliary genome in purple, and unique genome in yellow. 
 
 
 
 44 
Table 2.2. Differential predicted proteins identified by OrthoMCL between K. 
pneumoniae isolates. 
Predicted proteins present in WGLW5 and absent from WGLW1, 2, 3 Predicted proteins present in WGLW1, 2, 
3 and absent from WGLW5 
acetaldehyde_dehydrogenase__acet
ylating_ 
major_tail_sheath_protein aromatic_amino_acid_aminotransferase 
acetate_CoA_transferase_subunit_a
lpha 
major_tail_tube_protein aromatic_amino_acid_transporter_AroP 
acetate_CoA_transferase_subunit_b
eta 
membrane_fusion_protein_RaxA betaine_carnitine_choline_transporter__BCC
T__family_transporter 
acetoacetate_metabolism_regulator
y_protein_AtoC 
mercuric_resistence_transcriptional_repress
or_protein_MerD 
D_3_phosphoglycerate_dehydrogenase 
altronate_oxidoreductase molybdenum_pterin_binding_domain_cont
aining_protein 
diguanylate_cyclase__GGDEF__domain_co
ntaining_protein 
aminoglycoside_3__phosphotransfe
rase 
mRNA_interferase_PemK dihydrolipoyl_dehydrogenase 
antitoxin_PemI NodT_family_efflux_transporter__outer_m
embrane_factor__OMF 
fructose_bisphosphate_aldolase__class_I 
arsenate_reductase P_type_conjugative_transfer_ATPase_TrbB glutathione_S_transferase 
chlorophyll_synthesis_pathway_pro
tein_BchC 
P_type_conjugative_transfer_protein_TrbG glycerol_uptake_operon_antiterminator 
chromate_ion_transporter__CHR__
family_chromate_transporter 
P_type_conjugative_transfer_protein_TrbJ IS605_OrfB_family_transposase 
conjugative_transfer_signal_peptid
ase_TraF 
P_type_conjugative_transfer_protein_TrbL L_xylulokinase 
DGQHR_domain_containing_prote
in 
PBSX_family_phage_portal_protein LacI_family_transcriptional_regulator 
diguanylate_cyclase__GGDEF__do
main_containing_protein 
PFL2_glycerol_dehydratase_family_glycyl
_radical_enzyme 
low_calcium_response_locus_protein_S 
dihydrofolate_reductase_type_A13 phage_baseplate_assembly_protein_V LuxR_family_transcriptional_regulator__mal
tose_regulon_positive_regulatory_protein 
dihydropteroate_synthase_type_1 phage_tail_tape_measure_protein__TP901_
family__core_region 
lysozyme 
DNA__cytosine_5___methyltransfe
rase 
phage_virion_morphogenesis_protein MFS_transporter__ACS_family__glucarate_t
ransporter 
DNA_adenine_methylase plasmid_transfer_ATPase_TraJ O_antigen_export_system_ATP_binding_pro
tein_RfbB 
DNA_adenine_methylase portal_protein O_antigen_export_system_permease_rfbA 
DNA_repair_protein_RadC quaternary_ammonium_compound_resistan
ce_protein_qacE 
outer_membrane_usher_protein 
DNA_repair_protein_RadC RelB_DinJ_family_addiction_module_antit
oxin 
ParB_like_partition_protein 
efflux_transporter__RND_family__
MFP_subunit 
RelB_DinJ_family_addiction_module_antit
oxin 
phosphoglycerate_dehydrogenase 
general_secretion_pathway_protein
_S 
replication_A_protein protein_samA 
glycyl_radical_enzyme_activating_
protein_family 
short_chain_fatty_acids_transporter protein_TolA 
His_Glu_Gln_Arg_opine_family_a
mino_ABC_transporter 
signal_transduction_histidine_protein_kinas
e_AtoS 
PTS_system__galactitol_specific_IIC_comp
onent 
His_Xaa_Ser_repeat_protein_HxsA single_stranded_DNA_binding_protein pyruvate_dehydrogenase_complex_dihydroli
poamide_acetyltransferase 
His_Xaa_Ser_system_radical_SAM
_maturase_HxsB 
small_GTP_binding_protein_domain pyruvate_dehydrogenase_E1_component_su
bunit_alpha 
His_Xaa_Ser_system_radical_SAM
_maturase_HxsC 
sugar_porter__SP__family_MFS_transport
er 
pyruvate_dehydrogenase_E1_component_su
bunit_beta 
HK97_family_phage_major_capsid
_protein 
toxin_YkfI ribokinase 
HK97_family_phage_prohead_prot
ease 
transposase ribose_transport_system_substrate_binding_
protein 
HK97_gp10_family_phage_protein transposase_insC_for_insertion_element_IS
2H 
simple_sugar_transport_system_ATP_bindin
g_protein 
inner_membrane_protein_yagU transposase_insD_for_insertion_element_IS
2A_D_F_H_I_K 
simple_sugar_transport_system_ATP_bindin
g_protein 
insertion_element_IS1_8_protein_i
nsB 
transposase_insF_for_insertion_sequence_I
S3C 
simple_sugar_transport_system_permease 
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Table 2.2. Continued. 
integrase_recombinase transposase_insH_for_insertion_sequence_e
lement_IS5Y 
simple_sugar_transport_system_permease 
L_galactonate_transporter transposon_Tn3_resolvase simple_sugar_transport_system_permease 
lambda_family_phage_tail_tape_m
easure_protein 
type_I_restriction_enzyme_EcoprrI simple_sugar_transport_system_substrate_bi
nding_protein 
lambda_family_phage_tail_tape_m
easure_protein 
type_I_restriction_enzyme_EcoprrI_M_prot
ein 
single_stranded_DNA_binding_protein 
major_capsid_protein VirB4_family_type_IV_secretion_conjugal
_transfer_ATPase 
stable_plasmid_inheritance_protein 
  succinyl_diaminopimelate_desuccinylase 
  thiaminase__transcriptional_activator_TenA
_ 
  transposase_insC_for_insertion_element 
  TraR_family_phage_conjugal_plasmid_C_4_
type_zinc_finger_protein 
  UDP_galactopyranose_mutase 
  UPF0380_protein_yubP 
  UPF0401_protein_yubL 
  X_polypeptide 
 
Defining the minimal microbial community necessary for K. pneumoniae induced 
colitis in gnotobiotic Tbet-/- Rag2-/- mice. 
 
K. pneumoniae and P. mirabilis were sufficient to induce colitis in SPF-WT and 
SPF-Rag2-/- mice. However, neither bacterium alone or in combination was sufficient to 
induce inflammation in gnotobiotic Tbet-/- Rag2-/- mice despite successful colonization of 
the colon (127). This points to the necessity of an endogenous microbiota for K. 
pneumoniae and P. mirabilis to cause inflammation. To confirm that GF-Tbet-/- Rag2-/- 
mice are able to develop colitis, GF-Tbet-/- Rag2-/- mice were associated with stool from a 
prolapsed Tbet-/- Rag2-/- female with a SPF microbiota. Mice were sacrificed after a 4-
week (n=4) or 8-week (n=17) incubation, colons were processed for histology, and stool 
was processed for 16S rRNA amplicon sequencing. Colonic inflammation developed in 
the presence of a complex microbial community in these gnotobiotic mice (Figure 2.6A). 
The large distribution of colitis scores in gnotobiotic Tbet-/- Rag2-/- mice receiving fecal 
transplants prompted a further analysis of the associated metadata. While colitis score 
spread was not explained by caging effects, age, or length of fecal association, sex was a 
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significant contributing factor with male mice developing more severe disease than 
female littermates (Figure 2.6). 
There are several well-researched examples of sexual dimorphisms in bacterially 
mediated disease, often in the direction of increased male susceptibility. Studies have 
demonstrated increased LPS sepsis susceptibility in male mice and patients when 
compared to females (143).!Men display higher tuberculosis infection rates worldwide 
(144), and vaccination against Helicobacter pylori is less effective in male mice (145). 
Sexual dimorphisms in relation to human ulcerative colitis are controversial with some 
studies finding no differences in prevalence between the sexes (146-148) and other 
studies identifying a higher disease incidence in men (149, 150). While a sex bias was 
never observed in our SPF-Tbet-/- Rag2-/- colony, increased colitis severity in male 
gnotobiotic Tbet-/- Rag2-/- mice prompted us to examine the gut microbiota for colitis-
associated bacterial signatures. 
DNA was extracted from frozen stool collected on the day of mouse sacrifice. 
Library construction, amplification of the 16S V5-V6 region, and 454 pyrosequencing 
was performed by Research and Testing in Lubbock Texas. Sequences were processed 
with QIIME (Quantitative Insights Into Microbial Ecology) (81), revealing phylum level 
differences in bacterial abundance between individual mice and across mice grouped 
according to sex (Figure 2.7A). Next, LEfSe (Linear Discriminant Analysis with Effect 
Size) (83) was used to identify microbial clade differences between the sexes. LEfSe 
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Figure 2.6. Sexual dimorphism of colitis severity in gnotobiotic Tbet-/- Rag2-/- mice associated 
with stool from sick SPF-Tbet-/- Rag2-/- mice. (A) Histologic colitis scores from GF Tbet-/- Rag2-
/- mice associated with SPF-Tbet-/- Rag2-/- stool for 8 or 4 weeks. (B) Histologic colitis scores for 
the same mice as in (A), separated by sex. Symbols represent cages. The 4 males with the lowest 
colitis scores were associated for 4 weeks, all other mice were associated for 8 weeks. Mann-
Whitney statistical test, * P≤0.05. ** P≤0.01. 
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revealed an enrichment of Bacteroidetes in stool from sick male mice and an enrichment 
of Firmicutes in their healthier female littermates (Figure 2.7B). Specifically, OTUs 
from the families Rikenellaceae and Porphyromonadaceae were discriminate for male 
mice, and Bacilli and Clostridia for female mice. When comparing mice with low 
histologic score (0-4) to mice with severe colitis (5-8) regardless of sex, the Bacteroidetes 
and Firmicutes difference held (Figure 2.7C). Interestingly, Bacteroidetes species have 
been shown to induce colitis in mouse models, however, their abundance in diseased 
mice was not increased compared to healthy controls (151). In human 16S surveys, 
Rikenellaceae and Porphyromonadaceae are more abundant in control groups compared 
to IBD subjects (152), however mouse studies have identified enrichment of these 
families in disease groups of colitis induced by IL-22 deficiency!(153), in dextran sodium 
sulfate-induced colitis(154), and for Type I diabetes (6). 
 Comparing females to male mice housed in cage4 revealed a greater number of 
differential OTUs (Figure 2.8). In addition to the associations presented in Figure 2.7, 
male mice from cage4 had enrichments in the Actinobacteria and Proteobacteria (both 
beta and delta) phyla. Specifically, Desulfovibriaceae was associated with sick male mice 
in cage4. Desulfovibrio spp. have been identified at higher abundance in human patients 
with both acute and chronic ulcerative colitis (155). 
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Figure 2.7. Microbial signatures in the gut correlate with severity of intestinal inflammation 
and mouse sex. (A) Relative abundance of bacterial phyla in stool from GF-Tbet-/- Rag2-/- mice 
associated with stool from an SPF-Tbet-/- Rag2-/- mouse. Histologic colitis scores on top. (B) 
LEfSe plots showing significant differences in bacterial taxa between male and female mice and 
in (C) between mice with low and high colitis scores. LDA effect size on the bottom.!
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Figure 2.8. Discriminate bacterial taxa between female mice and a subset of male mice. 
Significant differences in bacterial phyla in stool from GF-Tbet-/- Rag2-/- mice associated with 
stool from an SPF-Tbet-/- Rag2-/- mouse LEfSe plot with LDA effect size along the bottom.!
!
!
!
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Establishing a gnotobiotic ASF-Tbet-/- Rag2-/- and ASF-WT mouse colony. 
 Having established that colonic inflammation can be recapitulated by a 
consortium of colonic bacteria in GF-Tbet-/- Rag2-/- mice, we sought to identify the 
minimal microbial community necessary to incite colitis. For these experiments, we 
established breeding colonies of gnotobiotic mice with a defined microbiota consisting of 
the 8 bacterial strains of the Altered Schaedler Flora (ASF) and housed in sterile 
isolators. GF-Tbet-/- Rag2-/- and GF-WT mice were orally inoculated with cecal contents 
of C3H/HeN:Tac gnotobiotic ASF mice obtained from Dr. Michael Wannemuehler of 
Iowa State University (156). Following a second inoculation one week later, ASF mice 
were bred. PCR confirmed that all pups of ASF associated breeders were positive for the 
8 ASF bacterial strains (Figure 2.9A). Presence of 7 of the ASF strains can be confirmed 
from DNA extracted from stool. Presence of ASF 361, an esophageal colonizer, was 
confirmed with a PCR on DNA extracted from cecal contents. Colonization with the ASF 
partially reversed the enlarged cecum phenotype observed in GF animals (Figure 2.9B), 
although ceca were still large in comparison to Balb/C SPF mice.  
In order to assess whether the ASF is a sufficient microbial community for K. 
pneumoniae driven colonic inflammation, F1 ASF-Tbet-/- Rag2-/- and ASF-WT mice were 
orally inoculated with K. pneumoniae WGLW5. While this isolate induces colitis in SPF 
mice (127), there were no signs of histologic colitis in ASF gnotobiotic mice after an 8-
week association with K. pneumoniae WGLW5 alone or in combination with P. mirabilis 
(Figure 2.10). Given the significantly reduced diversity of the ASF compared to SPF 
microbial communities, perhaps the ASF is too minimal of a community for K. 
pneumoniae induced colitis. Specifically, the absence of Bacteroidetes from the ASF is 
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Figure 2.9. Generation of gnotobiotic ASF colonies. (A) PCR confirmation of 8 ASF species in 
the F1 generation of ASF-Tbet-/- Rag2-/- breeders. DNA extracted from ceca upon sacrifice. (B) 
Enlarged cecum from an ASF-Tbet-/- Rag2-/- breeder associated in adulthood (left) and smaller 
cecum in her pup colonized with the ASF via parental transfer at birth (right). 
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troubling given the enrichment of this phylum in our 16S assessment of inflamed 
gnotobiotic mice (Figure 2.7 and 2.8). Additional strains can be associated in 
conjunction with the ASF for future fine-tune resolution of a colitogenic minimal 
microbial community. 
 
                         
Figure 2.10. K. pneumoniae and P. mirabilis do not induce colitis in ASF-Tbet-/- Rag2-/- mice. 
8 week associations in gnotobiotic isolators. Data points represent individual mice. Mann-
Whitney statistical test, *** P≤0.001. Tbet-/- Rag2-/-, TRUC. 
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V. DISCUSSION 
 As an opportunistic pathogen, K. pneumoniae thrives in an inflamed host 
environment and may participate in the initiation of an inflammatory state. While K. 
pneumoniae’s role in driving pneumonia and urinary tract infections is well defined, it is 
not widely accepted as a driver of inflammatory bowel disease. Several studies have 
identified an association between Crohn’s disease and Klebsiella in stool (157), but 
Klebsiella has not been implicated as a causative agent of disease.   
 Previous studies in mouse models of inflammatory bowel disease, specifically 
ulcerative colitis, revealed that a strain of K. pneumoniae isolated from mouse stool was 
able to induce colonic inflammation (127). The work of this thesis aimed to discover 
whether this effect was strain specific or a shared ability of human clinical K. 
pneumoniae isolates. Despite genomic diversity, 4 strains of K. pneumoniae, including 3 
isolates from humans, were able to drive ulcerative colitis in mice (Figure 2.2). These 
finding have implications for human health since K. pneumoniae is carried as part of the 
normal gut microbiota in 5-38% of the general population (85). Given the complex, 
multi-factorial nature of inflammatory bowel disease, it is attractive to speculate that 
carriage of K. pneumoniae in the gastrointestinal tract predisposes people to 
inflammatory bowel disease or puts inflammatory bowel disease patients at increased risk 
for flares. Even if not the initial cause of inflammation, native K. pneumoniae populations 
could presumably bloom and potentiate colitis in carriers. 
 Interestingly, we found that not all K. pneumoniae isolates are equally virulent in 
mouse models of systemic neonatal infection. The most important factor for the ability to 
incite severe infection was found to be the original host species and not anatomical 
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location since human stool K. pneumoniae did not lead to neonatal death but a murine 
stool isolate did (Figure 2.3). The differential ability of WGLW5 to cross epithelial 
barriers was confirmed by the finding of higher WGLW5 levels in mesenteric lymph 
nodes than any of the other K. pneumoniae isolates. Not only does the host seem to 
respond differently to K. pneumoniae WGLW5, but so does the gut microbiota. Fecal 
blooms of closely related P. mirabilis only in the presence of WGLW5 suggests that, 1) 
K. pneumoniae WGLW5 may indirectly change a colonic niche to make it more 
favorable to P. mirabilis growth, or that, 2) presence of K. pneumoniae WGLW5 may 
provide P. mirabilis with clues about the colonic environment. Further investigation of 
the genomic differences between K. pneumoniae WGLW2, 3, and 5 may reveal gene 
signatures associated with these observations.  
 A surprising finding of the studies presented in this chapter was evidence of 
sexual dimorphism in colitis severity when an SPF microbiota was transferred to 
genetically susceptible GF mice (Figure 2.6). As mentioned in the results section, while 
males are more susceptible to several bacterial-driven diseases, we had not previously 
observed increased male colitis severity in our SPF-Tbet-/- Rag2-/- colony. This suggests 
complexity in sexual dimorphism that may be mirrored in susceptibility of mice to 
diabetes. Non-obese diabetic (NOD) mice develop type I diabetes, with increased female 
susceptibility compared to males. However, when maintained under GF conditions, 
diabetes incidence is equivalent in male and female mice (158). Importantly, both host 
hormone and glycerophospholipid metabolite levels were different between SPF-NOD 
and GF-NOD mice. Perhaps the altered sex hormone milieu of male GF mice compared 
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to SPF controls could contribute to increased susceptibility to colitis in our GF-Tbet-/- 
Rag2-/- model. 
 Interestingly, the microbial abundance profile of the colitis-associated sexual 
dimorphism (Figure 2.7) was atypical in comparison to other microbiota-associated 
disease states. In both obese mouse models (159) and human populations (160), obesity is 
associated with an increased relative abundance of Firmicutes. The same pattern holds 
true for children with type I diabetes (161). In inflammatory bowel disease, a larger 
emphasis has been placed on an expanded Proteobacteria population in driving disease, 
however relative abundances of entire gut communities do show a decrease in 
Bacteroidetes in sick patients compared to controls!(162). Our 16S rRNA amplicon 
survey showed the opposite, with an enrichment of Bacteroidetes and depletion of 
Firmicutes in male mice with more severe colitis. These conflicting results may be due to 
microbiota composition changes driven by the altered development state of GF mice.  
Alternatively, studies have shown that almost every step in the 16S rRNA sequencing 
pipeline, from DNA prep, 16S amplification, and sequencing protocol, can significantly 
affect study output (163-165). Based on these findings, caution should taken when 
comparing results from 16S surveys across different methodologies, and with current 
knowledge, we may not be able to speculate on the biological relevance of the increased 
Bacteroidetes to Firmicutes ratio observed in our study. 
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VI. MATERIALS AND METHODS 
Bacterial strains and conventional culture 
K. pneumoniae WGLW5 (BEI HM-749) was previously cultured from the stool of 
BALB/c T-bet-/- Rag2-/- mice (127). K. pneumoniae WGLW1 (BEI HM-750), WGLW2 
(BEI HM-751) and WGLW3 (BEI HM-748) are clinical isolates cultured from human 
urine, sputum, and stool respectively. Bacteria were cultured in Luria-Bertani (LB) broth 
shaking aerobically at 37°C overnight or on MacConkey agar. For culturable K. 
pneumoniae CFU counts from stool, stool was collected from individual mice and 
serially diluted 10-fold using sterile PBS onto MacConkey agar and incubated for 24 h at 
37° C. Colonies were counted on plates with bacterial densities of 30-300 CFU. Log10 
CFU/ g stool bacteria were calculated after accounting for dry and wet fecal weights. 
ASF strains- Clostridium sp. (ASF356), Lactobacillus sp. (ASF360), 
Lactobacillus murinus (ASF361), Mucispirillum schaedleri (ASF457), Eubacterium 
plexicaudatum (ASF492), Firmicutes bacterium (ASF500), Clostridium sp. (ASF502), 
and Parabacteroides sp. (ASF519) were received from Iowa State University (156). 
SPF K. pneumoniae colonic inflammation model  
 4-week old SPF BALB/c Rag2-/- mice (Charles River, strain 028) were fed 
1.5x108 CFU K. pneumoniae isolate in 25 µl PBS from P200 pipette tips every third day 
for 8 weeks.  Mice were sacrificed and colons were processed for histology on day 56. 
Histology 
 At the time of sacrifice, colons were harvested, removed of colonic contents, and 
fixed in a solution of PBS with 4% paraformaldehyde. Tissue was paraffin embedded, cut 
into 0.5 um thick sections and stained with hematoxylin and eosin. Slides were scored by 
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pathologists in a blinded manner. Dr. Jonathan Glickman assigned colitis scores based on 
the cumulative sum of four criteria with a severity ranking between 0-4: mononuclear cell 
infiltration, polymorphonuclear cell infiltration, epithelial crypt hyperplasia, and 
epithelial injury. 0-absent, 1-mild, 2-moderate, 3-severe as described previously (166). 
Dr. Roderick Bronson assessed a subset of slides for edema and ranked samples 
according to severity. 1-low, 2-medium, 3-high. 
SPF K. pneumoniae neonatal infection model 
Beginning on the day of birth, SPF BALB/c Rag2-/- pups were sprinkled 
(cutaneous inoculation around the mouth) with 1.3 x 108 CFU K. pneumoniae in 20 µl 
PBS daily for 7 days. To confirm systemic K. pneumoniae infection in pups dying in this 
7-day window, K. pneumoniae CFU counts were assessed from the spleen and liver of a 
K. pneumoniae WGLW5 sprinkled pup dead for less than 4 hours, a sickly sprinkled pup, 
and its healthy sprinkled littermate. Tissue was treated similar to stool and assessed for K. 
pneumoniae CFU as explained previously. 7-weeks after the final K. pneumoniae 
inoculation, stool was assessed from surviving pups for culturable counts of K. 
pneumoniae and P. mirabilis as above.  
Real-time (RT)-qPCR 
Mesenteric lymph nodes were harvested at the time of mouse sacrifice and stored 
in RNAlater (Ambion) at -80° C. Tissue was washed with PBS prior to physical 
homogenization in QIAzol lysis reagent (Qiagen). RNA was extracted (Qiagan RNeasy 
Mini Kit), DNase treated, and reverse transcribed into cDNA (Bio-Rad iScript cDNA 
Synthesis Kit). RT-qPCR was performed using the SYBR FAST Universal qPCR Kit 
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(KAPA Biosystems). K. pneumoniae 23S expression was normalized to total bacterial 
16S expression. Primer sequences are shown in Table 2.3.                 
 
Table 2.3. K. pneumoniae 28S RT-qPCR primers. 
Primer Sequence 5’-3’ 
K. pneumo-OFF2551 GGTAGCACAGAGAGCTTG 
K. pneumo- OFF2552 ACTTTGGTCTTGCGAC 
 
K. pneumoniae comparative genomics 
The Klebsiella group sequencing project at the Broad Institute generated Illumina 
MiSeq whole genome sequences for WGLW1, 2, 3, and 5. These 4 genomes and the 
genomes of 5 previously published K. pneumoniae genomes (Table 2.1) were annotated 
by Prodigal. Genomes were translated to proteomes and matched to protein databases 
using BLASTP (http://blast.ncbi.nlm.nih.gov). OrthoMCL(113) was run to parse 
proteomes into protein groups representing orthologs, paralogs, and co-orthologs (141). 
An independent maximum likelihood phylogeny tool, RAxML (Randomized Axelerated 
Maximum Likelihood (142)), was used to generate a phylogenetic tree relating the 9 K. 
pneumoniae genomes used in this study.  
Gnotobiotic associations  
Stool from a prolapsed SPF-T-bet-/- Rag2-/- female was frozen in PBS at -80° C. 
Aliquots were thawed and fed from pipette tips to GF-T-bet-/- Rag2-/- and GF-WT mice 
bred and housed under sterile conditions in semi-rigid gnotobiotic isolators at Children’s 
Hospital Boston. After either 4 or 8 weeks, mice were sacrificed, their colons were 
processed for histologic examination of colitis, and stool was homogenized and stored in 
PBS at -80° C. 
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16S microbial community assessment 
DNA was extracted from stool that had previously been homogenized and stored 
at -80° C in PBS on the day of mouse sacrifice. DNA was extracted with phenol 
chloroform following mechanical bacterial lysis with 2 minutes of bead beating. 
Extracted DNA was sent to Research and Testing in Lubbock Texas for library 
construction and tag-encoded FLX amplicon bTEFAP 454 pyrosequencing with 8x 
coverage. Primers 784-1016 (167) (Table 2.4) were used to amplify the V5-V6 region of 
the 16S gene. Following sequencing, QIIME (81)!was employed for sequence processing. 
Following the standard QIIME workflow, sequences were subjected to denoising, 
inflation, OTU picking, chimera removal, and taxonomy assignment with Green Genes 
2011. Next, LEfSe (Linear Discriminant Analysis with Effect Size) (83)!was used to 
identify bacterial OTUs that were depleted or enriched due to mouse sex. 
Table 2.4. 16S primers used for microbial survey assessment. 
Primer Sequence 5’-3’ 
784F AGGATTAGATACCCTGGTA 
1061R_1 CRRCACGAGCTGACGAC 
 
ASF gnotobiotic colony generation 
For generation of ASF-T-bet-/- Rag2-/- and ASF-WT colonies, ceca from 
gnotobiotic C3H/HeN:Tac-ASF mice were thawed, and cecal contents were re-suspended 
under sterile conditions in PBS-0.5% cysteine. Aliquots were fed to GF-T-bet-/- Rag2-/- 
and GF-WT mice in gnotobiotic isolators. PCR on DNA isolated from stool with primer 
sets specific for each of the eight ASF strains (Table 2.5) was used to confirm 
colonization (168). Following the original association, all but ASF457 and ASF361 were 
confirmed in stool of associated gnotobiotic TRUC mice. One week later, a second 
association was performed to introduce ASF457, which requires the presence of other 
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microbes to reduce redox-potential of the host before successful colonization can occur. 
ASF361, an esophageal colonizer was confirmed vie PCR on DNA extracted from cecal 
contents upon sacrifice. 
 
Table 2.5. Primers for PCR confirmation of the 8 ASF flora in stool from gnotobiotic 
mice. 
ASF strain Forward Primer 5’-3’ Reverse Primer 5’-3’ 
ASF356 CGGTGACTAATACCGCATACGG CCTTGCCGCCTACTCTCCC 
ASF360 CTTCGGTGATGACGCTGG GCAATAGCCATGCAGCTATTGTTG 
ASF361 GCAATGATGCGTAGCCGAAC GCACTTTCTTCTCTAACAACAGGG 
ASF457 CCGAAAGGTGAGCTAATGCCGG GGGACGCGAGTCCATCTTTC 
ASF492 CTGCGGAATTCCTTCGGGG CCCATACCACCGGAGTTTTC 
ASF500 GTCGCATGGCACTGGACATC CCTCAGGTACCGTCACTTGCTTC 
ASF502 CGGTACCGCATGGTACAGAGG CAATGCAATTCCGGGGTTGG 
ASF519 CACAGTAAGCGGCACAGCG CCGCTCACACGGTAGCTG 
!
!
Statistical analyses  
Statistical calculations were performed using GraphPad Prism® software. Utilized 
tests include Mann-Whitney and one-way ANOVA with Dunnett’s post-test.
 62 
 
 
 
 
 
 
 
 
 
CHAPTER 3 
!
THE GUT MICROBIOTA AND HOST ANTIMICROBIAL PEPTIDES INFLUENCE 
KLEBSIELLA PNEUMONIAE CAPSULAR POLYSACCHARIDE POPULATION 
DYNAMICS 
!
 
 
 
 
 
 
 
 
 
 
 
 
 63 
I. ATTRIBUTIONS 
This chapter is adapted from a manuscript in preparation with the following authorship: 
Leslie Wardwell-Scott1, Sarah S. Wilson2, Xochitl C. Morgan3, Curtis Huttenhower3, 
Jason G. Smith2, Wendy S. Garrett1,4,5 
1 Departments of Immunology and Infectious Diseases and Genetics 
and Complex Diseases, Harvard T.H. Chan School of Public Health, 
Boston, MA, USA 
2 Department of Microbiology, University of Washington, Seattle, WA, 
USA  
3 Biostatistics Department, Harvard T. H. Chan School of Public 
Health, Boston, MA, USA 
4 The Broad Institute of MIT and Harvard, Cambridge, MA, USA 
5 Department of Medical Oncology, Dana-Farber Cancer Institute, 
Boston, MA, USA 
 
Leslie Wardwell-Scott performed all experiments and analyses, except as follows: the 
Klebseilla sequencing group at the Broad Institute performed whole genome sequencing 
of K. pneumoniae WGLW2, 3, 5. The Biopolymers Core of Harvard Medical School 
sequenced variants of K. pneumoniae WGLW5. Xochitl Morgan of Harvard T.H. Chan 
School of Public Health assembled and annotated the K. pneumoniae CPS variant 
genomes. Sarah Wilson of the University of Washington performed organoid 
experiments.  
!
II. ABSTRACT 
Klebsiella pneumoniae is a member of the gut microbiota of healthy individuals. 
Whether K. pneumoniae’s mucoid capsular polysaccharide (CPS) coat helps or hinders 
gastrointestinal tract colonization is unclear. To define a role for CPS in gastrointestinal 
colonization dynamics, K. pneumoniae biogeography was assessed in gnotobiotic mice. 
Naturally-arising K. pneumoniae variants with reduced CPS, which displayed enhanced 
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survival in response to bile salts and low pH, outcompeted mucoid populations 
throughout the gastrointestinal tract, except in the distal small intestine. Mucoid 
population levels correlated with regions of high Paneth cell antimicrobial peptide (AMP) 
expression and use of small intestinal organoid cultures revealed increased mucoid K. 
pneumoniae growth in the presence of Paneth cell α-defensins and decreased survival of 
non-mucoid variants. CPS also conferred an advantage when K. pneumoniae was part of 
a diverse microbiota. Introduction of a diverse microbiota to gnotobiotic mice colonized 
with K. pneumoniae resulted in a decline of non-mucoid variants, while mucoid 
populations remained stable. Inoculation of conventionally-reared mice with CPS 
variants revealed selective maintenance of mucoid K. pneumoniae populations, 
supporting that a CPS coat provides a competitive advantage against other bacteria in the 
densely populated, polymicrobial environment of the gastrointestinal tract. Enhanced 
survival of mucoid compared to non-mucoid variants in competition assays between K. 
pneumoniae and Escherichia coli in vitro reinforced this concept. Collectively, these data 
suggest that host AMPs, in combination with bacterial-bacterial interactions, shape 
population dynamics of K. pneumoniae and select for mucoid K. pneumoniae throughout 
the gastrointestinal tract. 
 
III. INTRODUCTION 
Klebsiella pneumoniae are species of Enterobacteriaceae that are responsible for 
nosocomial and opportunistic infections of the lungs, urinary tract, liver, and blood (169). 
Despite the clinical challenges K. pneumoniae presents, it coexists with other bacterial 
members of the gut microbiota in healthy human hosts. An estimated 5-38% of the 
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general population carries K. pneumoniae in their gastrointestinal tract; however these 
carriage numbers increase in hospital settings where up to 77% of caregivers and patients 
are K. pneumoniae positive (85). Regions of East Asia, such as Taiwan, also report these 
higher gastrointestinal carriage rates in healthy populations (121). Patient populations 
with K. pneumoniae liver abscesses have shown 100% co-colonization of the 
gastrointestinal tract, prompting the hypothesis that gastrointestinal carriage represents a 
predisposition for liver abscesses and serves as a general reservoir for K. pneumoniae 
disease (122). 
A defining feature of K. pneumoniae is its mucoid capsular polysaccharide (CPS) 
coat, which consists of glucuronic acid, glucose, variable additional sugars- typically 
mannose, rhamnose, or fucose (92). There are upwards of 80 K. pneumoniae CPS 
serotypes, which differ in composition of the CPS glycosyltransferase core and in 
incorporated sugars (93). Sequenced CPS gene clusters range in size from 21 to 30 kb 
with 16-25 open reading frames (93). K. pneumoniae capsule has been studied as a 
virulence factor (169), as CPS protects bacteria from phagocytosis (170, 171) and 
complement opsonization (172), facilitating evasion of host immune defenses (94). The 
majority of clinical isolates are mucoid, but variation resulting in loss of CPS production 
has been reported during in vitro culture (95, 173).  
Since the gastrointestinal tract is K. pneumoniae’s reservoir for disease (174), 
understanding K. pneumoniae population dynamics in mammalian gastrointestinal tracts 
in homeostatic states may inform studies of transmission and pathogenicity. A few 
studies have attempted to address the importance of CPS for gastrointestinal colonization 
with conflicting results that may be explained by use of different colonization 
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environments including germ-free (GF) chicken intestine (128) and antibiotic treated 
mice (129, 175). Experiments to deconstruct K. pneumoniae’s behavior in the 
gastrointestinal tract are challenging. In this environment K. pneumoniae must compete 
for space and nutrients with a multitude of bacterial species, while participating in a 
delicate balance with the host immune system. By mapping K. pneumoniae’s intestinal 
colonization biogeography, assessing colonization dynamics in GF and gnotobiotic 
mouse models, and using a small intestinal organoid culture system, we implicate CPS in 
inter-species bacterial interactions and protection against antimicrobial peptides produced 
by host Paneth cells in the small intestine. While CPS has been shown to be protective for 
K. pneumoniae during in vitro culture with antimicrobial peptides (176, 177), we 
elucidate factors shaping capsular variation in vivo. Herein, we define a role for K. 
pneumoniae CPS outside of the traditional virulence context and highlight the effect of 
bacterial interactions with other members of the microbiota on shaping populations of 
individual bacterial species. 
 
IV. RESULTS 
K. pneumoniae CPS loss following colonization of gnotobiotic mice. 
To assess K. pneumoniae colonization in the gastrointestinal tract, GF BALB/c 
mice were orally inoculated with murine K. pneumoniae strain WGLW5 (Figure 3.1A). 
K. pneumoniae WGLW5 has a mucoid CPS coat that is maintained in vitro. Beginning 
48h after inoculation, K. pneumoniae fecal isolates displayed diverse colony phenotypes 
distinguishable on MacConkey agar, a differential media for selective culture of 
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Enterobacteriaceae (Figure 3.1B, 4-wks post inoculation). 16S rRNA amplicon 
sequencing and a negative indole test confirmed that all isolates were K. pneumoniae.  
These K. pneumoniae isolates appeared to have reduced CPS (Figure 3.1B). To 
confirm decreased CPS production, we performed glucuronic acid measurement of 
bacterial membranes from five colonies representative of the diverse colony phenotypes 
isolated from K. pneumoniae mono-colonized mice. Glucuronic acid measurement 
demonstrated that K. pneumoniae isolates lacking a parent mucoid phenotype had 
significantly reduced CPS production (P ≤ 0.001) both on agar plates (Figure 3.1C) and 
in liquid culture (Supplemental Figure 3.1). We termed low CPS producing isolates 
non-mucoid variants (NMVs).  
An 8-wk K. pneumoniae colonization time course in GF mice (Figure 3.1A) 
revealed that the majority of recovered fecal K. pneumoniae isolates were NMVs as 
assessed by colony phenotype on MacConkey agar (Figure 3.1D). Although GF mice 
represent a model system for evaluating the behavior of single microorganisms in a host, 
GF mice have significant immune alterations compared to conventionally colonized mice 
(26). To address this issue, K. pneumoniae associations were repeated in gnotobiotic mice 
colonized with the Altered Schaedler Flora (ASF), a microbial community comprised of 
8 bacterial species found in the gut of healthy mice (168, 72). Although a simplified 
microbiota, the ASF in gnotobiotic mice promotes expansion of gut mucosal T-regulatory 
cell populations (73) and restores luminal IgA secretion (178). The absence of 
Proteobacteria and direct niche competition in the ASF led us to hypothesize that K. 
pneumoniae would readily colonize the gastrointestinal tract. While total K. pneumoniae 
fecal CFU were slightly reduced in ASF compared to GF mice (Supplemental Table  
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Figure 3.1. K. pneumoniae CPS population shift following GI colonization of gnotobiotic 
mice. (A) Gnotobiotic mouse K. pneumoniae association experimental chema. Dashed lines 
represent time points for stool sampling and CFU enumeration. (B) Fecal K. pneumoniae colonies 
on MacConkey agar after 4-week colonization of a germ-free (GF) mouse with WGLW5. Stars 
indicate mucoid (MUC) colonies, all others colonies are NMVs. (C) Glucuronic acid content of 
the membrane fraction of overnight K. pneumoniae variants grown on MacConkey agar. Data 
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(Figure 3.1 Continued ) reflect mean ± SD of 3 experiments. (D) 8-wk association of GF 
(squares) and ASF (circles) mice with WGLW5. MUC population (gray); NMV population 
(black). (E) Scale representation of CPS gene clusters of isolates assembled from WGSs. (F) 8-
wk association of ASF mice with the 3 isolates from (E). MUC population (gray); NMV 
population (black). For (D) and (F), data points represent mean population percentages ± SD for 
n=6 mice. ***, P ≤ 0.001, one-way ANOVA with Dunnett’s post-test. 
________________________________________________________________________ 
3.1), loss of CPS and out-competition of parental mucoid K. pneumoniae by NMVs were 
similar (Figure 3.1D). 
CPS gene clusters of murine K. pneumoniae (WGLW5) and two human clinical 
isolates (WGLW2- from human sputum, WGLW3- from human stool) were assembled 
from whole genome sequences (WGSs) (Figure 3.1E). Serotype identity was assigned 
using the wzc gene sequencing method, a recently described alternative to serum 
serotyping based on strain based differences in genomic sequences (179). K. pneumoniae 
WGLW5 was identified as serotype K25, WGLW3 was indeterminate, and WGLW2 was 
serotype K2. Despite diversity in CPS serotype, all three isolates displayed CPS variation 
when introduced into gnotobiotic ASF mice (Figure 3.1F), suggesting that reduction of 
K. pneumoniae CPS in a gnotobiotic host harboring a simplified gut microbial 
community is a shared feature of the species. 
CPS reduction is not likely caused by genetic mutation or plasmid loss.  
NMV K. pneumoniae does not revert to producing capsule under varied in vitro 
culture conditions or upon passage through mice (Table 3.1). To investigate if the NMV 
phenotype was driven by genetic mutation, WGSs were generated for 4 NMV and 2 
mucoid variants. After alignment to K. pneumoniae WGLW5, single nucleotide 
polymorphisms (SNPs) were identified between each CPS variant and the reference 
(Supplemental Table 3.2). There were no SNPs shared among NMV K. pneumoniae in 
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any single gene or in any predicated pathway across the sequenced genome, including 
within the CPS gene cluster. Additionally, plasmid profiles of all variants looked similar 
(Figure 3.2) arguing against plasmid loss leading to reduced CPS. 
 
Table 3.1. In vitro culture conditions and in vivo gnotobiotic associations with K. 
pneumoniae WGLW5 and corresponding shifts in CPS phenotype. Y indicates 
appearance of a different CPS phenotype from the starting population. N indicates no 
shift in CPS phenotype. MUC, mucoid; NA, non-applicable. 
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Figure 3.2. Plasmid profiles of mucoid (MUC) and NMV K. pneumoniae. Plasmids were 
isolated from overnight LB cultures using a Qiagen miniprep kit and visualized on a 1% agarose 
gel. 
 
 
 
We investigated whether the mucoid phenotype was driven by major genomic 
rearrangements by assembling genomes, aligning contigs to the WGLW5 scaffold, and 
aligning variant genomes with Progressive Mauve (180). Only NMV4 showed a 
significant chromosomal rearrangement (Supplemental Figure 3.2A). In agreement with 
the Progressive Mauve alignment, when reads were aligned to the WGLW5 reference 
genome, there were no disagreements in gaps between mucoid variants (Supplemental 
Figure 3.2B). Differences in genomic content were assessed by aligning assembly reads 
to each annotated gene.  After filtering proteins with poor sequencing coverage (median 
coverage > 2 IQR below 25th percentile), total divergence in genomic content was < 1.2% 
between variants, indicating low genomic loss (Supplemental Table 3.3). No genes were 
uniquely gained or lost between mucoid and NMV variants. 
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NMV K. pneumoniae display fitness advantages in response to environmental 
features of the gastrointestinal tract. 
 
Given that mice are coprophagic, mice in our gnotobiotic model are constantly re-
inoculating themselves with K. pneumoniae, sourced either from their littermates’ or their 
own stool. In this model of self-inoculation, K. pneumoniae would need to survive in the 
dry, aerobic environment of a desiccating stool pellet for several hours in between hosts. 
To assess whether mucoid K. pneumoniae is less fit outside the gut, we compared 
culturable counts of NMV and mucoid K. pneumoniae in stool pellets over a 24-hr air-dry 
desiccation period. Populations of mucoid vs. NMV K. pneumoniae did not change in this 
desiccation time period (Figure 3.3), suggesting that NMV population increases are 
driven by host factors and not by time spent ex vivo. 
 
 
Figure 3.3. K. pneumoniae populations do not shift after 24 hours in desiccated stool. Stool 
from ASF-WT mice associated for 5 days with K. pneumoniae WGLW5 was assessed for 
culturable K. pneumoniae counts following collection and after 24 hours of desiccation at room 
temperature. Data points represent a stool pellet from individual mice (n=6). Lines connect stool 
from the same mouse. 
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To identify host selective pressures contributing to K. pneumoniae CPS loss, we 
investigated the response of CPS variants to gastrointestinal tract environmental 
conditions. A barrier to gastrointestinal colonization is the stomach’s low pH. When 
challenged with low pH (pH 3.2; murine stomach pH is 3.0-4.0 (181)) more NMV K. 
pneumoniae survived than mucoid variants (P ≤ 0.05 - P ≤ 0.001) (Figure 3.4A). Also, 
NMVs population numbers recovered more quickly than mucoid K. pneumoniae 
following transfer from low pH to a neutral pH (Figure 3.4B). As an important control, 
in an absence of pH stress, NMV and MUC K. pneumoniae display similar growth 
dynamics, suggesting that MUC K. pneumoniae is able to grow as fast as NMVs in vitro 
(Supplemental Figure 3.3). 
Bile salts are another host selective pressure in the gastrointestinal tract. Bile salts 
are present throughout the small intestine at concentrations between 0.2-2% (182, 183). 
In the presence of physiological bile salt concentrations (1%), NMV K. pneumoniae grew 
faster than mucoid variants (Figure 3.4C). More mucoid K. pneumoniae died during 
incubation in 2% bile acid than NMVs (P ≤ 0.05 - P ≤ 0.001) (Figure 3.4D). The 
superior survival and growth of NMV K. pneumoniae in environmental conditions 
encountered along the gastrointestinal tract help explain how NMVs may outcompete 
mucoid variants during gastrointestinal colonization over the course of several weeks. 
CPS does not confer an advantage to K. pneumoniae in inflamed colons. 
A CPS coat has been shown to protect K. pneumoniae from the host immune 
response, for example, from phagocytosis by macrophages (170, 171) and complement 
opsonization (172). For this reason, and given that our gnotobiotic mice were free from 
histologic signs of colonic inflammation, we hypothesized that NMV K. pneumoniae 
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Figure 3.4. Fitness advantage of NMV K. pneumoniae in response to gastrointestinal tract 
environmental features. (A) Variant survival following incubation of overnight cultures in LB 
pH 3.2 for 2 h. Percentage survival compared to CFU counts prior to low pH. MUC- mucoid K. 
pneumoniae. (B) Recovery of variant CFU numbers following 2 h in LB pH 3.0 and resuspension 
in LB pH 6.8. (C) CFU growth curve of variants in the presence of 1% bile salts. (D) Variant 
survival following incubation of overnight cultures in 2% bile salts. Percentage survival 
compared to CFU counts prior to bile salt addition. Bars and data points represent mean ± SD of 
3 biological replicates. *** P ≤ 0.001, ** P ≤ 0.01, * P ≤ 0.05, one-way ANOVA with Dunnett’s 
post-test in (A), (D), and two-way ANOVA with Bonferroni post-tests in comparison to MUC 
parent in (B) and (C). 
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would be less fit in an inflamed colon. To test this hypothesis, ASF-Tbet-/- Rag2-/- and 
GF-Tbet-/- Rag2-/- mice were colonized with K. pneumoniae WGLW5 for 4-weeks. At 
this time point, the fecal K. pneumoniae population is dominated by NMV variants 
(Figure 3.1D). Mice were then administered either 1.5% or 3% dextran sodium sulfate 
(DSS) in their drinking water for 9 days to induce epithelial injury and inflammation. 
Histology revealed that in the gnotobiotic ASF setting, 3% DSS induced colitis and 1.5% 
did not (Figure 3.5A). Fecal K. pneumoniae counts measured prior to and after DSS 
administration revealed an increase in fecal K. pneumoniae in the presence of DSS. 
Mucoid K. pneumoniae populations significantly increased in mice treated with both 
1.5% and 3% DSS (Figure 3.5B), despite an absence of histologic colitis in mice 
receiving the lower dose. While mucoid K. pneumoniae increased in an inflamed colon, 
numbers of NMV K. pneumoniae did not significantly change. 
 Despite pre-established NMV K. pneumoniae populations being unaffected by the 
onset of inflammation in a pre-colonized colon, we asked whether inflammation prior to 
colonization would confer a competitive advantage to mucoid K. pneumoniae 
populations. ASF-WT mice were treated with 3% DSS for 5 days prior to inoculation 
with mucoid WGLW5. Counts of fecal K. pneumoniae over the course of 8 days on DSS 
revealed that inflammation did not stop the appearance of NMV K. pneumoniae (Figure 
3.5C). Rather, the mucoid K. pneumoniae population slightly decreased by the end of the 
experiment compared to control mice. All mice had signs of histologic colitis (Figure 
3.5D). Take together, these DSS experiments suggest that inflammation does not confer a 
competitive advantage to mucoid K. pneumoniae in the setting of the colon. These  
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Figure 3.5. NMV K. pneumoniae colonization is not adversely affected by DSS-induced 
inflammation in the colon.  (A) Histologic colitis score of colons from gnotobiotic ASF-TRUC 
mice associated with K. pneumoniae WGLW5 and administered 1.5% (n=6) or 3% DSS (n=8) in 
drinking water for 9 days. Control- DSS-free drinking water (n=8). (B) Log10 CFU/gram stool K. 
pneumoniae counts from stool before (pre) and after (d9) DSS administration in drinking water. 
Same mice as in (A), with the addition of WGLW5 colonized GF-TRUC receiving 3% DSS 
(n=8). (C) ASF-TRUC mice administered 3% DSS for 5 days, followed by colonization with 
mucoid (MUC) WGLW5. Counts of fecal K. pneumoniae were collected for 8 days following 
colonization and recorded as MUC colonies as a percentage of the whole K. pneumoniae 
population. 3% DSS continued for full length of experiment. n=6 for each group. (D) Histologic 
colitis score from mice from (C). Date points represent individual mice in (A), (C), (D). *** P ≤ 
0.001, ** P ≤ 0.01, * P ≤ 0.05, Mann-Whitney U test. 
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experiments also suggest that an absence of inflammation does not explain appearance of 
a large NMV population in our gnotobiotic mice. 
CPS confers a competitive advantage to K. pneumoniae in the presence of a diverse 
microbiota. 
 
Although we identified gastrointestinal tract selective pressures favoring NMV 
population expansion, emergence of spontaneous NMVs was not observed in our 
specified pathogen free (SPF) mice. To determine whether a more diverse microbiota 
could affect K. pneumoniae CPS shifts, ASF mice were colonized with K. pneumoniae 
for 4-wks and then inoculated with the colonic contents of SPF mice with no prior K. 
pneumoniae exposure. 8-wks after diverse microbiota inoculation, culturable counts of 
fecal K. pneumoniae decreased by several logs (Figure 3.6A). Fecal mucoid K. 
pneumoniae decreased by an average of 0.11 log10 CFU/g stool. In contrast, there was a 
large decline in NMV K. pneumoniae (average decrease of 2.3 log10 CFU/g stool; P ≤ 
0.01) (Figure 3.6B), suggesting that NMV K. pneumoniae is less fit when part of a 
diverse microbial community.  
During host colonization and transmission, K. pneumoniae does not have the 
colonization advantage seen in our gnotobiotic model and must establish itself in the 
presence of many microbes. To address this, we developed a colonization model that 
introduced K. pneumoniae to mice concurrently with other symbionts. SPF pups were 
sprinkled with either mucoid or NMV K. pneumoniae daily for 7d beginning on their date 
of birth (Figure 3.6C)). 3-weeks after the final K. pneumoniae exposure, stool CFUs 
were quantified. Mucoid K. pneumoniae stably colonized SPF pups, whereas NMV K. 
pneumoniae were below the limit of fecal culture-based detection (3.7 log10 CFU/g stool, 
P ≤ 0.01) (Figure 3.6C) and did not revert to producing CPS. Mucoid K. pneumoniae did  
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Figure 3.6. CPS affords K. pneumoniae a competitive advantage in the presence of a diverse 
microbiota. (A) ASF-WT mice (n=6) with a 4-wk established K. pneumoniae population were 
associated with stool from SPF mice. Total K. pneumoniae log10 CFU/g stool decline over 8-wks 
in the presence of SPF microbiota. Lines follow individual mice. (B) Change in mucoid (MUC) 
and NMV populations after 8-wks with a SPF-stool microbiota (from mice in A). (C) K. 
pneumoniae stool counts from 4-wk old SPF mice sprinkled with K. pneumoniae variants for 7d 
following birth (MUCparent, NMV3, and PBS n=9; MUC1 and NMV2 n=12). Counts were taken 
3 wks after cessation of K. pneumoniae sprinkling. Limit of detection (LOD), 3.7 log10 CFU/g 
stool (dashed line). (D) E. coli stool counts from mice in (C). MUC group includes E. coli counts 
from pups sprinkled with MUCparent and MUC1; NMV group includes NMV2 and NMV3. 
Symbols in (C) and (D) represent individual mice. (E) in vitro competition between K. 
pneumoniae variants and E. coli. Each symbol represents survival of a K. pneumoniae isolate 
compared to growth in the absence of E. coli. *** P ≤ 0.001, ** P ≤ 0.01, Mann Whitney test. In 
(C), undetectable samples were given a value of the LOD for statistical analysis. 
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not give rise to NMVs in SPF mice, unlike the results of GF and gnotobiotic associations. 
These experiments also revealed that fecal E. coli levels differed between groups 
receiving a PBS control or CPS variants. Mucoid-sprinkled pups showed the lowest E. 
coli levels, whereas pups receiving PBS were colonized at much higher levels (P ≤ 0.001) 
(Figure 3.6D). 
While colonization resistance and niche fulfillment may play a role in balancing 
related bacteria in the gastrointestinal tract, direct inter-bacterial warfare is also possible 
(184, 185). To determine if E. coli and K. pneumoniae have an antagonistic relationship, 
competition assays were performed against an E. coli isolated from stool of a SPF-Tbet-/- 
Rag2-/- mouse (termed TRUC E. coli from here on). Since the K. pneumoniae variants 
described above had adapted to a GF environment in the absence of bacterial competition 
for 4-wks prior to isolation, competition experiments utilized 4 mucoid and 4 NMV K. 
pneumoniae isolates cultured from stool of GF mice colonized for only 1.5 wks with K. 
pneumoniae. Although all K. pneumoniae isolates were adversely affected by the 
presence of E. coli, mucoid K. pneumoniae displayed enhanced survival compared to 
NMVs (Figure 3.6E).  
The TRUC E. coli genome contains multiple anti-bacterial systems that may 
contribute towards K. pneumoniae killing. 
 
 To investigate the antagonistic relationship observed between TRUC E. 
coli and K. pneumoniae, we performed a genomic analysis of our TRUC E. coli isolate. 
The TRUC E. coli genome was sequenced on an Illumina MiSeq by the Biopolymers 
Core of Harvard Medical School. After adapter trimming and removal of low quality 
reads, the Velvet assembler (186) was used for genome assembly, leading to a genome 
with 86 contigs. Genome annotation was performed with PROKKA (187). 
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Comparison of the TRUC E. coli genome to three additional gastrointestinal E. 
coli isolates with Progressive Mauve (180) revealed similar genome organization and 
overlap with E. coli LF82 (Figure 3.7A), an adherent and invasive (AIEC) strain 
originally isolated from the stool of a patient with Crohn’s disease (188). TRUC E. coli 
displayed more breaks in homologous sequences, called local collinear blocks, or LCBs, 
with E. coli UM146, an AIEC strain from stool of a patient with Crohn’s disease (189) 
(Figure 3.7B), SE11 from stool of a healthy human (190) (Figure 3.7C), and K12 
MG1655, from the stool of a patient with gastroenteritis (191) (Figure 3.7D). This close 
genomic relationship between AIEC LF82 and TRUC E. coli was confirmed with the 
BLAST Ring Image Generator (BRIG) (192) (Figure 3.8). 
Understanding that many differences observed between bacterial strains of the 
same species can be driven by genetic content contained on plasmids and within mobile 
genetic elements, the genomic island content of TRUC E. coli was assessed with Island 
Viewer (193). Island Viewer integrates the SIGI-HMM and IslandPath-DIMOB 
prediction methods. SIGI-HMM uses a hidden Markov Model to measure codon usage 
and IslandPath-DIMOB looks for genome regions with altered GC content relative to the 
whole genome, codon bias, transposases, and integrases. Island Viewer revealed that the 
majority of TRUC E. coli’s genomic island content is not shared with the LF82 genome 
and is unique to TRUC E. coli (Figure 3.9). 
Island Viewer predicted 1327 genes contained within genomic islands for TRUC 
E. coli. 54% of this list mapped to hypothetical proteins according to PROKKA 
annotation. The 610 predicted proteins with annotation were binned into functional 
categories that include toxins and effector molecules, secretion and efflux systems, outer 
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membrane virulence factors, and phage (Table 3.2). This analysis revealed two loci for 
Type VI secretion systems (T6SS) within TRUC E. coli’s genome. 
 
 
           
Figure 3.7. Mauve alignment of the TRUC E. coli genome to other gastrointestinal E. coli 
isolates. Rearrangement of the TRUC E. coli genome in comparison to the human E. coli isolates 
LF82 (A), UM146 (B), SE11 (C), and MG1655 (D). Vertical red lines mark contig boundaries of 
assembled genomes. Lines connecting genomes show rearrangements of local collinear blocks 
(LCBs). Homologous sequence without rearrangements are represented as rectangular LCBs. 
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Figure 3.8. BLAST ring image of TRUC E. coli genome compared to 8 human 
gastrointestinal E. coli isolates. Image generated with BRIG. White spaces correspond to 
genomic content present in TRUC E. coli and absent from the associated human isolate. 
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Figure 3.9. Genomic island content of TRUC E. coli. Island Viewer output showing genomic 
island content for TRUC E. coli aligned to E. coli LF82. Yellow- SIGI-HMM prediction method, 
blue- IslandPath-DIMOB prediction method, red- integrated results. Green circle rim represents 
shared genomic content between TRUC and LF82 E. coli. Gray circle rim shows the genomic 
content unique to TRUC E. coli. 
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Table 3.2. Predicted genomic island content of TRUC E. coli. Functional categories of 
genes predicted to lie within genomic islands using Island Viewer.  
 
Functional 
Category 
TRUC and LF82  
Shared Accessory Proteins 
Unique TRUC  
Accessory Proteins 
D
N
A
 
ed
iti
ng
 Restriction enzymes  
Transcription factors None 
Cas1/3/6 and CRISPR associated proteins  
T
ox
in
s a
nd
 
ef
fe
ct
or
 
m
ol
ec
ul
es
 
Virulence activator VirF (TF)  
Toxin RTX-1 Toxic protein SymE 
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Sialic acid transport system 
Chemotaxis 
Quorum sensing 
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Flagella 
Adhesin YadA 
Phage Bacteriophage proteins (lambda and others) Prophage 
 
 Given the emerging role of T6SS in bacterial inter and intra species competition, 
we further defined the T6SS loci identified within the TRUC E. coli genome. While 
PROKKA labeled the majority of the genes in these regions as hypothetical proteins, 
manual BLAST comparisons revealed relationships to previously defined T6SS loci 
(Figure 3.10). Comparison of TRUC E. coli’s two T6SS loci to those studied in other E. 
coli isolates revealed a strong similarity in gene presence and organization to LF82, 
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uropathogenic, and avian pathogenic E. coli (194). Of the two loci identified, T6SS1 is 
thought to contribute to bacterial competition while T6SS2 has been implicated in the 
pathogenesis of meningitis (194). The strain specific regions of T6SS loci  (light gray 
region in Figure 3.10) typically contain effector proteins. BLAST did not reveal 
annotated matches for TRUC-specific T6SS genes, however PGAP1-like protein domains 
have been found in effector proteins from other T6SS loci (195, 194) and it is possible 
that this protein in TRUC E. coliÕs T6SS1 loci plays a role in bacterial killing. 
Experiments with E. coli T6SS1 mutants should be performed to confirm a role for T6SS 
in interactions with K. pneumoniae. 
 
 
 
Figure 3.10. T6SS1 and T6SS2 of TRUC E. coli. T6SS were defined using a combination of 
PROKKA annotation and manual BLAST comparisons. Gene labeling according to the scheme 
used by Ma, et al. 2014. Predicted protein family, domain, or motif recorded below gene label. 
Loci shown to scale. Genes shaded light gray represent regions unique to TRUC E. coliÕs T6SS 
loci as assessed by BLAST. All other genes are found in previously identified E. coli T6SS loci. 
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Biogeography of mucoid K. pneumoniae populations correlate with regions of high 
Paneth cell antimicrobial expression in the gastrointestinal tract. 
 
Despite NMV K. pneumoniae’s fitness advantages over mucoid variants in the 
absence of bacterial competition, a small population of mucoid K. pneumoniae was 
maintained in gnotobiotic animals throughout an 8-wk colonization (Figure 3.1D, F). To 
investigate maintenance of mucoid populations, we explored K. pneumoniae’s 
biogeography throughout the gastrointestinal tract. The gastrointestinal tracts of ASF 
mice were divided into 7 sample sites (Supplemental Figure 3.4A). Culturable counts of 
K. pneumoniae were taken from the luminal contents and associated mucosa at each site. 
Total K. pneumoniae in luminal contents increased sequentially along the gastrointestinal 
tract (Figure 3.11A). NMV K. pneumoniae predominated throughout most of the 
gastrointestinal tract in both luminal and mucosal sites with the exception of the distal 
small intestine, where the proportion of mucoid K. pneumoniae spiked (Figure 3.11B). 
The distal small intestine also had the highest gene expression of lysozyme 1 (Figure 
3.11C) and cryptdins, mouse enteric α-defensins (Figure 3.11D), which are antimicrobial 
peptides (AMPs) released by Paneth cells (196). There was a direct relationship between 
high mucoid K. pneumoniae populations and high host cryptdin expression (Spearman 
correlation, r=0.39, P=0.015) (Figure 3.11E). Mucoid K. pneumoniae levels did not 
follow the expression pattern of AMPs produced by colonic epithelial cells (mouse β-
defensin3, Supplemental Figure 3.4B), suggesting that AMPs produced specifically by 
Paneth cells may shape K. pneumoniae CPS population distribution in the gut. 
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Figure 3.11. Biogeography of mucoid (MUC) K. pneumoniae populations correlate with 
regions of high Paneth cell AMP expression in the gastrointestinal tract. (A) Total K. 
pneumoniae CFU recovered from luminal contents throughout the gastrointestinal tract. Proximal 
(p), mid (m), distal (d), and cecum (c). Missing data points correspond to gastrointestinal regions 
with no luminal content at the time of the experiment. (B) Luminal and mucosal MUC K. 
pneumoniae populations throughout the Gastrointestinal tract as a percentage of total K. 
pneumoniae. Host Lysozyme1 (C) and general cryptdin (D) expression along the gastrointestinal 
tract. (E) Positive Spearman correlation between samples sites with high MUC populations and 
high host cryptdin expression. Shaded symbols represent distal SI site, open symbols represent all 
other sites. For (A) and (B) symbols connected by lines represent individual mice (n=8), for (C) 
and (D) box and whiskers show mean ± SD for n=6 mice, in (E) symbols represent single sample 
sites from n=6 mice. 
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CPS protects K. pneumoniae from killing by Paneth cell α-defensins. 
Based on the correlation between mucoid K. pneumoniae and high host cryptdin 
expression, we hypothesized that CPS provides K. pneumoniae with an advantage in the 
presence of α-defensins in vivo. We tested the sensitivity of K. pneumoniae to α-
defensins and found increased killing activity against NMVs compared to mucoid K. 
pneumoniae with cryptdin 23 (Crp23, produced by mouse Paneth cells, Figure 3.12A), α-
defensin 1 (HNP1, produced by human neutrophils, Figure 3.12B), and α-defensin 5 
(HD5, produced by human Paneth cells, Figure 3.12C) (P ≤ 0.05 - P ≤ 0.001), 
supporting the conclusion that CPS protects K. pneumoniae from host α-defensins. 
Mucoid K. pneumoniae is also protected from killing by β-defensins (Supplemental 
Figure 3.5), but as the geography of expression does match mucoid K. pneumoniae 
colonization (Supplemental Figure 3.4B), these AMPs may be less of a selective 
pressure or be present at too low concentrations in the colons of healthy mice to impact 
K. pneumoniae population dynamics.  
Small intestinal organoids can be cultured from primary stem cells present in 
intestinal crypts. They model the complex small intestinal epithelium and contain its full 
complement of differentiated cells types (196). Using microinjection into organoids to 
model luminal bacterial exposure within the gastrointestinal tract, Paneth cell α-defensins 
have been shown to restrict bacterial growth in organoids (197). However, bacterial 
growth was not restricted in organoids produced from Mmp7-/- mice, which lack active 
Paneth cell α-defensins but are otherwise physiologically normal (198). To address the 
effects of CPS on K. pneumoniae exposed to naturally secreted Paneth cell α-defensins, 
we compared the growth of mucoid and NMVs after microinjection into wild-type (WT)  
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!
!
Figure 3.12. CPS protects K. pneumoniae against killing by Paneth cell AMPs. Relative 
survival of mucoid (MUC) and NMV variants in the presence of murine Crp23 (A), human HNP1 
(B), and human HD5 (C). Relative survival as compared to untreated samples. (D) Image of a 
small intestinal organoid in culture (top). Relative survival of CPS variants in organoids with 
Paneth cell cryptdin production (WT) compared with organoids defective in cryptdin production 
(Mmp7-/-). *** P ≤ 0.001, ** P ≤ 0.01, * P ≤ 0.05, one-way ANOVA with Dunnett’s posttest.  
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and Mmp7-/- small intestinal organoids. A significant (2-4 fold; P ≤ 0.05 - P ≤ 0.001) 
growth inhibition was seen with all NMVs in the WT organoids compared to growth in 
Mmp7-/- organoids (Figure 3.12D). In contrast, mucoid K. pneumoniae growth actually 
increased in WT organoids (Figure 3.12D). These data support that increased sensitivity 
of NMVs to AMPs, specifically α-defensins, imposes selective pressure in the mouse 
small intestine during colonization. 
 
 
V. DISCUSSION 
!
The diverse and dense microbial environment of the mammalian gastrointestinal 
tract has made understanding the response of bacterial populations to individual features 
of the gastrointestinal environment challenging. GF and gnotobiotic mouse models with 
minimal microbial communities allowed us to disentangle contributions from the host 
and microbiota in shaping spatial population dynamics of the gut symbiont, K. 
pneumoniae, along the gastrointestinal tract. While the presence of a mucoid CPS coat 
was a handicap for K. pneumoniae when subjected to the harsh gastrointestinal conditions 
of bile salts and a low pH in vitro (Figure 3.4), maintenance of mucoid populations in the 
distal small intestine, and more importantly, absence of NMV populations in the 
gastrointestinal tracts of conventionally colonized mice, suggested the presence of other 
significant selective pressures.  
In tracing the biogeography of K. pneumoniae CPS populations along the 
gastrointestinal tract, Paneth cells emerged as selective pressure favoring mucoid K. 
pneumoniae. While prior work has demonstrated in vitro resistance to cationic AMPs by 
K. pneumoniae and other encapsulated bacteria (176, 177), determining if and how this 
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shapes K. pneumoniae CPS populations in vivo has remained elusive. Not only did 
mucoid K. pneumoniae tolerate direct exposure to physiologic levels of purified AMPs 
better than NMVs (Figure 3.12A-C), but mucoid K. pneumoniae also displayed 
enhanced growth in the presence of naturally secreted Paneth cell AMPs in small 
intestinal organoids (Figure 3.12D). This finding speaks to a growing body of research 
suggesting that microbes actively sense and respond to host immune molecules, with one 
of the most striking examples being activation of quorum sensing and virulence pathways 
in Pseudomonas aeruginosa upon binding of host interferon γ to the bacterial outer 
membrane porin OprF (199). With respect to AMPs, polymixin B or neutrophil defensin 
1 exposure has been hypothesized to increase K. pneumoniae CPS production (176) and 
to globally alter K. pneumoniae gene expression (200). A recent report on the influence 
of AMPs on gastrointestinal bacterial communities found that several common gut 
symbiotic bacteria share high levels of resistance to AMPs (201). Additionally, 
differential α-defensin expression influences the composition of symbiotic bacterial 
populations in SPF mice (202). Collectively, these studies support the importance of 
Paneth cells in influencing bacterial colonization of the host (203).  
In this study, we also identified an advantage conferred by CPS when K. 
pneumoniae is part of a complex gastrointestinal microbiota (Figure 3.6). The selective 
pressure of a diverse microbiota was best exemplified during K. pneumoniae colonization 
of SPF mice inoculated as neonates (Figure 3.6C). Neonatal Paneth cell numbers remain 
low until post-natal day 28 (204), suggesting that the selective pressure of Paneth cell α-
defensins was minimal in these mice and highlighting the strong influence of the 
microbiota. There have been contradictory data on the role of capsule when K. 
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pneumoniae colonizes the gastrointestinal tract (128, 175). The most recent direct 
investigation of this question reported equivalent gastrointestinal colonization between 
mucoid and non-mucoid mutants as measured by fecal bacterial counts in streptomycin 
treated mice (175), which harbor a markedly perturbed gut microbiota. Streptomycin 
depletes the gastrointestinal tract of many potential K. pneumoniae competitors, such as 
other members of the γ-Proteobacteria (34), including E. coli, which we found had an 
antagonistic relationship with K. pneumoniae (Figure 3.6E). Additionally, fecal CFU 
counts of K. pneumoniae recovered from streptomycin treated mice in Struve et al. are 
several logs higher than those that we observed in SPF mice and are equivalent to 
colonization levels we observed in gnotobiotic associations (Supplemental Table 3.1). 
Thus, the data of Struve et al. are not in conflict with our observations, but rather, support 
our findings on NMV expansion in gnotobiotic ASF associations (Figure 3.1) and that 
gut microbial community diversity is a selective pressure for K. pneumoniae CPS 
maintenance.  
Further studies are needed to define the precise role that CPS plays in K. 
pneumoniae’s interactions with other bacteria. We hypothesize that CPS may aide K. 
pneumoniae in several ways. Unfortunately, the mechanism of CPS loss in NMVs 
remains indeterminate. Genomic analyses did not reveal SNPs or large deletions shared 
among NMVs that could explain CPS loss (Supplemental Table 3.2). Genes regulating 
CPS production, such as rmpA, are often carried on plasmids (101); however, NMV 
plasmid profiles were similar to mucoid profiles (Figure 3.2). K. pneumoniae with CPS 
coats grow faster as a biofilm as compared to engineered NMVs (205). Biofilms in the 
gut have been found attached to food particles, and bacteria residing in gut biofilms are 
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known to digest complex carbohydrates at different rates than non-aggregated bacteria 
(206). Perhaps CPS, by aiding in the establishment of a fast-growing biofilm, help K. 
pneumoniae sequester and utilize resources more efficiently than NMV K. pneumoniae 
when competing with many other bacteria for the same pool of resources.  
Alternatively CPS may afford K. pneumoniae a competitive advantage in a 
complex microbiota through physical protection from direct bacterial interactions. Given 
the mechanistic similarities between host AMPs and bacterially produced antimicrobials 
(207), CPS may protect K. pneumoniae against bacterially produced antimicrobials. In 
support of this concept, we observed increased survival of mucoid K. pneumoniae as 
compared to NMVs during in vitro competition experiments with a murine E. coli isolate 
(Figure 3.6E). While little research to date has focused on competition between K. 
pneumoniae and E. coli specifically, antagonistic relationships can exist between bacteria 
of the same phylum, family, and often species in polymicrobial environments such as the 
Gastrointestinal tract (208). 
The cache of antimicrobial weaponry employed by bacteria against other bacteria 
includes microcins, contact-dependent inhibition (CDI), and type VI secretion of protein 
effectors. Gram-negative bacteria produce many AMPs. For example, the E. coli AMP, 
microcin7, exhibits antimicrobial activity against K. pneumoniae (209). In addition to 
released bacterial toxins such as microcins and colicins, E. coli can deliver toxins using 
methods that require cell-to-cell contact with a targeted bacterium. While type VI 
secretion (T6SS) were initially described in relation to host-pathogen interactions (210), 
extensive work in Vibrio cholera and Pseudomonas aeruginosa has established a role for 
this system in intra- and inter-species bacterial warfare (211, 212). T6SS loci have been 
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reported in many species of Proteobacteria, including E. coli (213). Investigation of the 
genome of the E. coli used in our studies revealed presence of two T6SS loci and a 
predicted microcin, which may contribute to the inhibitory interaction we observed 
against K. pneumoniae. Just as CPS can physically protect K. pneumoniae from 
antimicrobials in solution, CPS may restrict access of CDI or T6SS machinery to the cell 
surface proteins required for CDI, or to the bacterial periplasm necessary for T6SS. 
Collectively our data suggest that CPS is an important defense mechanism against attack 
from both host and bacterial cells. In the gastrointestinal tract of conventional mice, the 
host and the gut microbiota likely act in tandem to select for a mucoid K. pneumoniae 
population. This begins with Paneth cell AMPs in the distal small intestine and is 
followed by increased microbial density and diversity throughout the colon. By 
maintaining a mucoid K. pneumoniae population in the ileum, the host has selected K. 
pneumoniae to be a more effective competitor in the lower gastrointestinal tract. This 
host-microbiota co-maintenance of mucoid K. pneumoniae populations, which represent 
the most virulent clinical isolates, may explain why the gastrointestinal tract is a 
significant reservoir for human K. pneumoniae disease. While CPS has classically been 
studied as a means to evade the host immune system, we define the importance of mucoid 
CPS for when K. pneumoniae becomes part of the polymicrobial environment of the 
colon. Overall, our study suggests that bacterial-bacterial interactions may be equally, if 
not more important than host factors in influencing the population dynamics of a single 
bacterial species within the gastrointestinal tract. 
 
 
 95 
VI. MATERIALS AND METHODS 
Bacterial strains and culture conditions 
K. pneumoniae WGLW5 (mucoid parent; BEI HM-749) and the murine E. coli 
strain were previously cultured from stool of BALB/c T-bet-/- x Rag2-/- (TRUC) mice 
(127). MUC1, NMV1, NMV2, NMV3, and NMV4 are WGLW5 derivatives isolated 
from stool after a 4-week passage of WGLW5 through a GF mouse. K. pneumoniae 
strains used in competition with E. coli were isolated after 1.5-week passage of WGLW5 
through a GF mouse. K. pneumoniae WGLW2 (BEI HM-751) and WGLW3 (BEI HM-
748) are clinical isolates cultured from human sputum and stool respectively. Bacteria 
were cultured in Luria-Bertani (LB) broth shaking aerobically at 37°C overnight or on 
MacConkey agar. Growth curves (Fig. 2c) were conducted in 6 mL LB with overnight 
bacteria diluted 1:500.  
ASF strains- Clostridium sp. (ASF356), Lactobacillus sp. (ASF360), 
Lactobacillus murinus (ASF361), Mucispirillum schaedleri (ASF457), Eubacterium 
plexicaudatum (ASF492), Firmicutes bacterium (ASF500), Clostridium sp. (ASF502), 
and Parabacteroides sp. (ASF519) were obtained from Iowa State University (214). 
Animal husbandry  
SPF mice were housed in microisolator cages in the Harvard T. H. Chan School 
of Public Health barrier facility. Mouse studies were approved and carried out in 
accordance with Harvard Medical School’s (HMS) Standing Committee on Animals and 
the N.I.H. guidelines for animal use and care. GF and gnotobiotic mice were bred and 
maintained under sterile conditions in gnotobiotic isolators at Children’s Hospital Boston. 
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Female and male BALB/c mice aged 6-12 weeks were used for GF, gnotobiotic, and SPF 
experiments unless noted. Mice were bred in house unless noted.  
Culture-based studies of fecal and mucosal K. pneumoniae populations 
GF and gnotobiotic-ASF mice we orally inoculated with ~1x108 K. pneumoniae 
suspended in PBS (or 50 µl of feces resuspended in PBS). An equal amount was spread 
on their fur and anus. At indicated time points, stool was collected from individual mice 
and serially diluted 10-fold using sterile PBS onto MacConkey agar for K. pneumoniae 
culturable counts after 24 h at 37° C. Colonies were counted on plates with bacterial 
densities of 30-300 CFU. Log10 CFU/ g stool bacteria were calculated after accounting 
for dry and wet fecal weights. Mucoid and NMV populations are presented as 
percentages of total K. pneumoniae CFU. 
For the stool desiccation study, pellets were collected from individual mice and 
half of each sample was plated for CFU enumeration after weight measurements. The 
remaining stool sample was allowed to dry for 24 hours at room temperature. Following 
this desiccation period, samples were weighed and serial diluted onto MacConkey agar 
for the final CFU count. 
SPF pup inoculation 
Beginning on the day of birth, SPF BALB/c pups (Charles River) were sprinkled 
with 1.5 x 108 CFU K. pneumoniae in PBS daily for 7 days. 3-weeks after the final K. 
pneumoniae inoculation, stool was assessed for culturable counts of K. pneumoniae and 
E. coli. Individual colonies were re-streaked onto Tryptic Soy Agar (TSA) for 18 h at 
37°C and screened for indole production (BD DMACA Indole reagent). Indole (-) K. 
pneumoniae stained pink; indole (+) E. coli stained blue. 
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Gnotobiotic DSS colitis model 
ASF-TRUC mice were associated with K. pneumoniae WGLW5 for 4 weeks. 
Stool was collected and plated for culturable K. pneumoniae counts on MacConkey agar. 
Drinking water was amended with 1.5% or 3% DSS (Affymetrix), filter sterilized. After 8 
days on DSS, stool was plated and mice were sacrificed. Colons were harvested and 
processed for histology. 
In a second experiment, ASF-TRUC mice were administered 3% DSS in drinking 
water for 5 days, followed by colonization with K. pneumoniae WGLW5. Counts of fecal 
K. pneumoniae were collected for 8 days following colonization. 3% DSS continued for 
full length of experiment 
Histology 
 At the time of sacrifice, colons were harvested, colonic contents were removed, 
and tissues were fixed in a solution of PBS with 4% paraformaldehyde. Tissue was 
paraffin embedded, sectioned into 0.5 um thick sections and stained with hematoxylin 
and eosin. Blinded slides were scored by Dr. Jonathan Glickman. Colitis scores were 
assigned based on the cumulative sum of four criteria with a severity ranking between 0-
4: mononuclear cell infiltration, polymorphonuclear cell infiltration, epithelial crypt 
hyperplasia, and epithelial injury. 0-absent, 1-mild, 2-moderate, 3-severe as described 
previously (166).  
Glucuronic acid measurement 
K. pneumoniae CPS production was assessed by measuring the glucuronic acid 
content (215, 216) of extracted bacterial CPS (217). 100 µl of 1% Zwittergent 3-14 
(Sigma) in 100 mM citric acid was added to 500 µl of a washed overnight K. pneumoniae 
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culture re-suspended in PBS or to a PBS solution containing an overnight K. pneumoniae 
colony from agar. Following incubation for 30 min at 50° C and centrifugation, 250 µl 
supernatant was added to 1 mL ethanol. After precipitation at 4° C for 30 min, samples 
were spun, supernatants were removed, pellets were dried for 20 min on ice, and capsular 
material was resuspended in 200 µl H2O. Glucuronic acid was measured by adding 1.2 
mL 12.5 mm tetraborate in concentrated H2SO4 to 200 µl aliquots of D-glucuronic acid 
standards (Sigma) and extracted K. pneumoniae CPS. Samples were heated at 70° C for 5 
min. 20 µl of a 0.15% 3-phenylphenol (Sigma) in 0.5% NaOH were added to cooled 
tubes. Samples were vortexed, and 520nm absorbances were recorded after 10 min. CPS 
concentrations were reported as fg glucuronic acid per CFU based on initial culture 
concentrations. 
K. pneumoniae genomic analyses 
CPS gene clusters for WGLW2, 3, and 5 were defined by BLAST comparisons of 
genes in the known vicinity of CPS clusters using whole-genome sequences (WGSs) 
generated by the Klebsiella group Sequencing Project, Broad Institute of Harvard and 
MIT.  
 MiSeq WGSs of MUCparent, MUC1, NMV1, NMV2, NMV3, and NMV4 were 
generated by the HMS Biopolymers Core. Burrows-Wheeler Aligner (BWA) was used to 
align variant reads to the WGLW5 reference genome. SNPs were identified using 
Samtools (http://samtools.sourceforge.net). Raw sequence reads have been deposited in 
NCBI’s SRA. Table 3.3 lists accession IDs. 
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Table 3.3. K. pneumoniae whole-genome sequence submissions. 
Isolate Source 
Capsule 
Phenotype 
WGS 
Sequence 
Data Database 
Accession 
 
WGLW2 human sputum mucoid assembled and annotated 
NCBI 
GenBank GCA_000300675.1 
WGLW3 human stool mucoid assembled and annotated 
NCBI 
GenBank GCA_000300935.1 
WGLW5 murine stool mucoid assembled and annotated 
NCBI 
GenBank GCA_000300955.1 
MUC parent passaged WGLW5 mucoid raw .fastq reads 
NCBI 
SRA SRR1743357 
MUC 1 
MUC parent derivative 
after passage through 
GF mouse 
mucoid raw .fastq reads 
NCBI 
SRA SRR1743361 
MUC 1 
resequenced 
MUC parent derivative 
after passage through 
GF mouse 
mucoid raw .fastq reads 
NCBI 
SRA SRR1743377 
NMV 1 
MUC parent derivative 
after passage through 
GF mouse 
non-
mucoid 
raw .fastq 
reads 
NCBI 
SRA SRR1743362 
NMV 2 
MUC parent derivative 
after passage through 
GF mouse 
non-
mucoid 
raw .fastq 
reads 
NCBI 
SRA SRR1743364 
NMV 3 
MUC parent derivative 
after passage through 
GF mouse 
non-
mucoid 
raw .fastq 
reads 
NCBI 
SRA SRR1743365 
NMV 4 
MUC parent derivative 
after passage through 
GF mouse 
non-
mucoid 
raw .fastq 
reads 
NCBI 
SRA SRR1743366 
NMV 4 
resequenced 
MUC parent derivative 
after passage through 
GF mouse 
non-
mucoid 
raw .fastq 
reads 
NCBI 
SRA SRR1743379 
   
Assembly and annotation of strains 
150 bp paired-end Illumina reads from each strain (Parent, MUC1, NMV1, NMV2, 
NMV3, and NMV4) were assembled with SPAdes assembler v 3-5-0 (218). Scaffolds for 
each strain were annotated with Prokka (187), using the flag “–kingdom Bacteria.” All 
scaffolds, gene annotations, and code are available for download at 
http://huttenhower.sph.harvard.edu/klebsiella2015/ 
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Ordering of scaffolds 
The WGLW5 reference genome (GenBank; GCF_000300955.1) contains 10 
scaffolds. To determine their putative placement, we used Contiguator (219) to align 
them to chromosome 1 of the completed genome K. pneumoniae strain MGH78578 
(gi|150953431|gb|CP000647.1). In this manner, we partitioned the scaffolds of the 
WGLW5 genome into four ordered genomic scaffolds and six plasmids (lengths 337582, 
139159, 40758, 26040, 24319, and 4470 bp). We used this ordered WGLW5 scaffold 
created by Contiguator as a reference to order the scaffolds of all other assemblies, then 
used ProgressiveMauve (180) to assess genomic rearrangement on chromosome 1. 
Determination of assembly gaps  
For each assembly, bowtie2 (220) was used to align reads to chromosome 1 of the 
reference genome WGLW5. Bedtools (221) was used to calculate coverage for each 
alignment, as detailed in the script “bed.sh”.  The resulting tracks were visualized with 
Integrative Genome Viewer (7).   
Conservation of genomic content 
In order to assess whether gene content was conserved between strains, for each 
gene, we used bowtie2 (220) to align reads from each strain. We then calculated median 
coverage across all bases for each gene using bedtools (222). We removed  low-coverage 
outlier genes, defined as ( coverage < (25th percentile -  (2 * interquartile range))) for 
each genome. !
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TRUC E. coli genomic analyses 
 The TRUC E. coli genome was sequenced on an Illumina MiSeq by the 
Biopolymers Core of Harvard Medical School. Adapter trimming was performed with 
Trimmomatic (223). Low quality bases were removed with a trailing score of 20 and a 
sliding window of 20. Velvet (186) was used for genome assembly with a Kmer of 85 
and minmum contig length of 200 base pairs, and PROKKA (187) was used for genome 
annotation. 
 Comparison of the TRUC E. coli genome to three additional gastrointestinal E. 
coli isolates was undertaken using Progressive Mauve (180). The BLAST Ring Image 
Generator (BRIG) (192) confirmed genomic relationships between TRUC E. coli and 8 
additional E. coli isolates. 
Island Viewer (193) identified genes predicted to fall on genomic islands, and 
BLAST was used to more fully define and annotate the T6SS loci of TRUC E. coli. 
K. pneumoniae survival assays 
Altered pH and bile acid 
Overnight cultures of K. pneumoniae were washed in PBS and re-suspended in an 
equal volume of LB pH 3.0 (amended with hydrochloric acid) or LB with 2% Difco Bile 
Salts No. 3 (BD). Surviving CFU were enumerated after shaking at 37°C for 2 h. 
Percentage survival compared to initial bacterial concentrations. 
Human and mouse α-defensins  
Overnight K. pneumoniae cultures were diluted 20x into fresh LB and incubated 
at 37°C for 1 h with shaking. Cultures were diluted to OD600 0.5 with 10 mM PIPES and 
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1% tryptic soy broth (PIPES-TSB). Bacteria were washed 2x and resuspended in 1 mL 
PIPES-TSB. After a 1:10 dilution in PIPES-TSB, 25 µl bacteria were mixed with 7.5 µM 
HNP1 (Abcam), HD5 (Hycult Biotech), or Crp23 (purified by reverse-phase high-
pressure liquid chromatography from oxidative refolding of partially purified linear 
peptides (224)). Samples were incubated at 37°C for 2 h with shaking before CFU 
enumeration. Percentage relative survival in comparison to untreated bacterial samples. 
E. coli competition killing 
Competition assays were performed as previously described (211). Briefly, 
overnight cultures of E. coli and K. pneumoniae were washed and diluted 100x into LB. 
After 2.5 h at 37°C with shaking (OD600 of ~0.8), bacteria were centrifuged at 10,000 X 
g and resuspended to an OD600 of ~10. K. pneumoniae and E. coli were mixed 1:1, 5 µl 
were spotted onto LB agar, and plates were incubated at 37°C for 2 h. Agar spots were 
resuspended in 1 mL PBS. CFU were enumerated on MacConkey agar. Percent relative 
survival in comparison to K. pneumoniae spotted in the absence of E. coli. 
Biogeography of K. pneumoniae in the gastrointestinal tract 
The Gastrointestinal tracts of gnotobiotic mice associated with K. pneumoniae 
WGLW5 for 4-weeks were divided into 7 sections: equal thirds of the small intestine 
representing the proximal, middle, and distal small intestine; the cecum; and equal thirds 
of the colon representing the proximal, middle, and distal colon. Luminal contents and 
host tissue were taken at each site for K. pneumoniae counts and RNA extraction (tissues 
preserved in RNAlater, Ambion). A PBS wash removed residual luminal content from 
tissue samples. Luminal and washed mucosal samples were homogenized in PBS and 
plated for enumeration. 
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Real-time (RT)-qPCR 
Tissue in RNAlater was washed with PBS prior to physical homogenization in 
Qiazol. RNA was extracted (Qiagan RNeasy Mini Kit), DNase treated, and reverse 
transcribed into cDNA (Bio-Rad iScript cDNA Synthesis Kit). RT-qPCR was performed 
using the SYBR FAST Universal qPCR Kit (KAPA Biosystems). Gene expression was 
normalized to β–actin expression. Primer sequences are shown in Table 3.4. 
!
Table 3.4. Primer sequences used in RT-qPCR expression studies. 
Primer Sequence 5’-3’ 
ActB 987 (forward)1 TACCACCATGTACCCAGGCA 
ActB 1083 (reverse) 
{Martinon:2010kt} 
CTCAGGAGGAGCAATGATCTTGAT 
Cryptdina (forward)!
{Hashimoto:2012bx} 
TCCTCCTCTCTGCCCTYGTCCTG 
Cryptdina (reverse)!
{Hashimoto:2012bx} 
CTCTTCTCCTGGCTGCTCCTC 
LYZ1 (forward)!
{Hashimoto:2012bx} 
GCCAAGGTCTACAATCGTTGTGAGTTG 
LYZ1 (reverse)!
{Hashimoto:2012bx} 
CAGTCAGCCAGCTTGACACCACG 
mBD3 (forward)!
{RivasSantiago:2006fd} 
TCTGTTTGCATTTCTCCTGGTG 
mBD3 (reverse) 
{RivasSantiago:2006fd} 
TAAACTTCCAACAGCTGGAGTGG 
 
a  These primers are labeled DEFA1!(225); however, because they 
recognize many Crp isoforms, we consider them a general measure of Crp 
expression. 
 
Small intestinal organoid production, maintenance, and microinjection  
Organoids from WT and Mmp7-/- mice, both on a C57BL/6NHsd background 
(224), were cultured in growth factor reduced Matrigel (BD Biosciences) and Complete 
Crypt Culture Medium (CCCM) and microinjected as previously described (197). 3 days 
prior to microinjection, organoids were subcultured, deposited in 30 µl Matrigel on glass 
coverslips in 12-well tissue culture dishes, and overlaid with 1 mL CCCM without 
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antibiotics. On the day of the experiment, overnight cultures in LB were diluted 1:20 to a 
final volume of 10 mL in LB. After 1 h at 37°C with shaking, 1 mL was washed 2x and 
resuspended in 100 µl of PBS. One needle was used to microinject 20 organoids of each 
genotype, which comprised a single sample. Each organoid received ~5x102 CFU. 
Samples were incubated in CCCM without antibiotics for 1 h, followed by 1 h with 100 
µg/mL gentamicin. Organoids were washed 2x with Advanced DMEM/F12 and grown in 
CCCM without antibiotics. At 9 h post-injection, organoids were removed from Matrigel 
using Cell Dissociation Solution (BD Biosciences) at 4° C for 30 min, pelleted at 300 x g 
for 5 min, and resuspended in 100 µl sterile water for 5 min to lyse eukaryotic cells. 
Samples were vortexed for 15 sec before serial dilution onto LB agar. Relative survival 
as a percentage of CFU recovered from WT organoids divided by Mmp7-/- organoids. 
Statistical Analyses 
Statistical calculations were performed using GraphPad Prism® software. Utilized 
tests include Mann-Whitney, one-way ANOVA with Dunnett’s post-test, two-way 
ANOVA with Bonferroni post-tests, and Spearman correlation. 
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CHAPTER 4 
!
CONCLUSIONS AND FUTURE DIRECTIONS 
!
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I. CONCLUSIONS 
 Klebsiella pneumoniae is a clinically important bacterium that causes many 
infections in susceptible patients and is a growing cause for concern for patients and 
infectious disease specialists because of its ever-increasing antibiotic resistance. One of 
the reasons K. pneumoniae can spread so quickly in hospital and community settings is 
because this bacterium can be carried as part of the gastrointestinal microbiota of healthy 
individuals. This thesis explores K. pneumoniae in the setting of its principal reservoir for 
human disease- the gastrointestinal tract. 
Expanding on previous work with murine-derived K. pneumoniae (127), we find 
that human clinical isolates are also able to drive colonic inflammation in mice regardless 
of their original organ of isolation. Although all isolates could drive inflammation, only 
WGLW5, an isolate of mouse origin, was able to move beyond the gastrointestinal tract, 
as reflected by presence of this bacterium in mesenteric lymph nodes. Through 
gnotobiotic associations we also observed a previously unidentified sexual dimorphism in 
colitis severity in the Tbet-/- Rag2-/- mouse model of ulcerative colitis. Colitis was found 
to be more severe in male mice. 
Many virulent K. pneumoniae isolates possess a mucoid capsule. This thesis 
assesses the importance of capsule for K. pneumoniae survival in the gastrointestinal 
tract. Our data suggest that Paneth cell antimicrobial peptides exert selective pressure that 
favors mucoid K. pneumoniae populations. In addition to defining host factors that 
influence K. pneumoniae populations, this study reveals that K. pneumoniae’s capsule 
provides it with a competitive advantage against other bacteria in the gastrointestinal 
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tract, providing compelling evidence for biological relevance of capsule beyond 
traditional virulence functions. 
 
II. LIMITATIONS AND FUTURE DIRECTIONS 
Small panel of K. pneumoniae isolates 
One limitation of these studies is the small panel of K. pneumoniae isolates tested 
(Chapter 2). Ideally, comparative genomic approaches should reveal genome signatures 
of virulence depending on host adaptation and original site of K. pneumoniae isolation. 
However, with only 1 murine isolate, it is difficult to draw conclusions about gene 
selection specific to host species. Additionally, since our isolates were taken from diverse 
tissue sites, we could not relate auxiliary genome content to selection for specific 
environments (eg. colon vs. nasopharynx vs. urinary tract). This issue was further 
complicated by the finding the K. pneumoniae WGLW5, taken from murine stool, is 
more genetically similar to the human sputum isolate than the human stool isolate. Future 
studies would benefit from inclusions of larger pool of K. pneumoniae isolates collected 
from different hospitals and diverse organ sites. 
Minimal microbial community necessary for K. pneumoniae driven inflammation 
Another limitation of this work lies in the inability to define the minimal 
microbial community necessary for K. pneumoniae to drive colonic inflammation 
(Chapter 2). As addressed previously, the ASF likely represents too minimal of a 
gnotobiotic microbial community to recapitulate the results of feeding K. pneumoniae to 
SPF mice.  This could be due to lack of essential interactions between K. pneumoniae and 
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other bacteria in the microbiome, or due to a deficiency in immune development and 
response driven by gnotobiotic communities.  
Moving forward, several approaches could be utilized to further define microbial 
community requirements for K. pneumoniae driven disease. Continuing to leverage 
gnotobiotics, individual bacterial species can be added to the ASF. Taking inspiration 
from Andrew Goodman’s consortium (74) and from a lack of Bacteroidetes in the ASF, 
Bacteroides thetaiotamicron and Bacteroides vulgatus represent promising initial 
candidates. Observations from this thesis suggest that K. pneumoniae interacts with 
closely related species of Proteobacteria in the gastrointestinal tract (Figure 2.3C, 
Figure 3.6D, E). For this reason, inclusion of another Proteobacteria, such as E. coli, to 
gnotobiotic ASF mice may change K. pneumoniae’s behavior in the gastrointestinal tract 
in a way that promotes inflammation of host tissue.  
Conversely, instead of building a microbiota from scratch in gnotobiotic mice, a 
full microbiota can be systematically depleted of bacterial groups with antibiotics in vivo. 
After identifying differential combinations of antibiotics that allow or prevent K. 
pneumoniae associated colonic inflammation, 16S rRNA amplicon sequencing of DNA 
from stool will help identify necessary strains. 
Method of CPS variation 
A significant limitation of the work presented in Chapter 3 is an incomplete 
understanding of the nature of capsule loss in NMVs of K. pneumoniae. While stability of 
the NMV phenotype both in vitro and in vivo argues for a genetic basis of decreased 
capsule production, comparison of genome sequences in a SNP analysis, gene presence 
and absence screen, and an assessment of genome rearrangements did not reveal any 
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shared or likely mechanisms that could explain the NMV phenotype. Given that NMVs 
appear gradually over time in gnotobiotic mice and that the NMV phenotype manifests in 
heterogeneous colony morphology, one interpretation of our results is that there are likely 
many genomic events that could lead to capsule loss. If each of the 4 NMV isolates is 
producing less capsule due to independent mutations, our approach of using comparative 
genomics and looking for shared genome changes will not provide answers. While we 
attempted to account for this by expanding our analysis to search for mutations in shared 
functional pathways, this was not an exhaustive strategy.  
Another interpretation of our findings is that the NMV phenotype is driven by 
changes in gene expression rather than gene loss or mutation. While stability of the NMV 
phenotype seems to argue against phase variation or expression changes, it is possible 
that with complex regulation we have not been able to mimic the environment necessary 
to induce capsule re-expression in CPS variants. Several experimental procedures could 
be attempted in the future to assess the contribution of gene expression to capsule loss in 
NMV K. pneumoniae. 
RNAseq could be used on capsule variants to measure differential gene 
expression and look for commonalities among NMV variants. A caveat to this approach 
is that the regulatory network involved in capsule production for K. pneumoniae is not 
fully worked out. While well studied transcription factors such as rmpA and rmpA2 are 
known to increase capsule expression, most K. pneumoniae isolates do not carry the 
plasmids containing these regulatory elements and, yet, still maintain high CPS 
expression (101). Coupled with the heterogeneity of the NMV phenotype and possibility 
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of several mechanisms contributing to CPS loss, RNAseq results have the potential to be 
difficult to interpret. 
In order to assess epigenetic control of capsule production in NMV K. 
pneumoniae, the methylation status of the genome could also be addressed. Sequencing 
with the Pacific Bioscience (PacBio) SMRT sequencing technology can identify modified 
pieces of bacterial DNA (226). PacBio sequencing reveals carbon-5-methylated 
cytosines, nitrogen-6-mehtylated adenines, and nitrogen-4-methylated cytosines (227). 
Methylation has been shown to be involved in the regulation of pili expression in E. coli 
(228), LPS expression in Legionella pneumophila (229), and could represent an as yet 
unidentified regulatory mechanism for CPS expression in K. pneumoniae. 
An important control to use in studies of K. pneumoniae CPS moving forward is 
an isogenic isolate with CPS deficiency resulting from a defined mutation. Deletion of 
highly conserved genes in the CPS gene cluster, such as gnd or galF, using the lambda 
Red recombination system (230) may generate such a strain. 
Paneth cell deficient mice 
 In Chapter 3, we use small intestinal organoids from mice that either lack or 
produce mature cryptdins to show that MUC K. pneumoniae has a growth advantage in 
the presence of physiological concentrations of host antimicrobial peptides. While a 
better experimental system than in vitro killing assays, organoids do not fully replicate 
the conditions that K. pneumoniae would be experiencing in a live animal. Future 
experiments would benefit from the use of gnotobiotic mouse models with Paneth cell 
AMP deficiencies. These models include both the Mmp7-/- mice (198) that were used for 
organoid generation in Chapter 3 and ATG16L1HM mice. These mice are hypomorphic 
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for a Crohn’s disease susceptibility risk allele and have been shown to be deficient in 
Paneth cell release of AMPs (14). If capsule is truly protective against host AMPs, in an 
absence of functional Paneth cells NMV K. pneumoniae would be expected to fully 
overtake MUC K. pneumoniae in the small intestine of GF or gnotobiotic ASF mice. 
Summary 
 This thesis explores the relationship between the capsule of K. pneumoniae, other 
bacteria, and the host throughout the gastrointestinal tract. We implicate capsule in 
protecting K. pneumoniae from direct killing by antimicrobial peptides produced by 
Paneth cells in the small intestine and from killing by E. coli. Studies diving deeper into 
the mechanism of antagonism between K. pneumoniae and E. coli will further define the 
importance of capsule in interactions between bacteria. Given the clinical burden of K. 
pneumoniae, complete knowledge of this bacterium’s colonization factors could aide in 
novel preventative and therapeutic approaches to eliminate K. pneumoniae from the 
gastrointestinal tract of carriers.  
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Supplemental Figure 3.1. Reduced glucuronic acid content of NMV K. pneumoniae isolates. 
Membrane fractions were isolated from overnight mucoid (MUC) and NMV variants in liquid LB 
culture and assessed for glucuronic acid concentration via acid hydrolysis. Bars represent mean ± 
SD of 3 biological replicates. ***, P ≤ 0.001, one-way ANOVA with Dunnett’s post-test. 
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Supplemental Figure 3.2. Comparative genomic analyses of K. pneumoniae variants. (A) 
ProgressiveMauve alignments of the scaffolds of K. pneumoniae variants MUC1, NMV1, NMV2, 
NMV3, NMV4, and Parent. (B) The distribution of gaps in chromosome 1 of the genomes of K. 
pneumoniae variants MUC1, NMV1, NMV2, NMV3, NMV4, and Parent, relative to WGLW5 
reference genome. 
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Supplemental Figure 3.3. Growth curve of K. pneumoniae variants in LB broth. Overnight 
cultures diluted 1:500 into 6mL fresh LB and grown shaking at 37°C. Aliquots serial diluted onto 
MacConkey agar for CFU counts every hour for 8 hours. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0 1 2 3 4 5 6 7 8
1.0×1006
1.0×1007
1.0×1008
1.0×1009
1.0×1010
MUC parent
MUC 1
NMV 1
NMV 2
NMV 3
NMV 4
hrs in LB
lo
g 1
0 C
FU
/m
L
 116 
 
Supplemental Figure 3.4. Biogeography of K. pneumoniae and host AMP expression 
throughout the gastrointestinal tract. (A) Experimental schema for biogeography assessments. 
At 7 samples sites along the gastrointestinal tract of ASF mice, luminal contents and mucosal 
tissue were harvested for K. pneumoniae CFU counts and host tissue expression studies. (B) β-
defensin3 expression throughout the gastrointestinal tract of n=6 mice. 
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Supplemental Figure 3.5. β-defensin killing of K. pneumoniae variants. Relative survival of 
MUC (gray) and NMV (black) K. pneumoniae variants in response to 2-hr killing assays with β-
defensin 3 at increasing concentrations.  
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Supplemental Table 3.1. Average log10CFU/g stool and SD of K. pneumoniae in stool 
from gnotobiotic and specified pathogen free associations.  
 
 
 
Microbiota 
collection 
time point 
(weeks) 
corrected 
log10CFU/g 
stool 
K. pneumoniae WGLW5 8 8.9 ± 0.1 
ASF + K. pneumoniae WGLW5 8  7.6 ± 0.5 
ASF + K. pneumoniae WGLW5 + SPF stool 8  6.3 ± 0.6 
SPF + K. pneumoniae WGLW5 sprinkling 4  4.4 ± 0.5 
SPF + K. pneumoniae MUC1 sprinkling 4  4.7 ± 0.7 
ASF + K. pneumoniae WGLW2 8  7.6 ± 0.9 
ASF + K. pneumoniae WGLW3 8  8.5 ± 0.05 
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Supplemental Table 3.2. Samtools SNP output of K. pneumoniae variant whole-genome 
sequences aligned to reference genome WGLW5. 
! ! !
 
K. pneumoniae 
variant 
# SNPs (aligned to 
WGLW5 
reference) 
# SNPs 
within CPS 
cluster 
# genes with 
SNPs shared 
among NMVs 
# KEGG pathways 
with SNPs shared 
among NMVs 
MUC parent 130 0 NA NA 
MUC 1 176 0 NA NA 
NMV 1 137 0 0 0 
NMV 2 137 0 0 0 
NMV 3 132 1a 0 0 
NMV 4 162 0 0 0 
 
a Synonymous substitution in wcaJ 
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Supplemental Table 3.3. Gene coverage similarity between K. pneumoniae variants. Each 
column represents one variant. Each row shows the number of genes in the column variant that 
are not found in the genome of the row variant.  
!
 
PARENT 
(5316 
genes) 
MUC1 
(5366 
genes) 
NMV1 
(5308 
genes) 
NMV2 
(5388 
genes) 
NMV3 
(5310 
genes) 
NMV4 
(5267 
genes) 
notPARENT 0 14 14 25 14 13 
notMUC1 0 0 4 11 4 2 
notNMV1 20 28 0 31 22 22 
notNMV2 2 2 2 0 2 0 
notNMV3 12 14 14 21 0 15 
notNMV4 54 58 57 65 60 0 
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